combine O
this O
with O
previous O
study O
, O
seem O
likely O
that O
the O
transport O
step O
over O
the O
plasma O
and O
tonoplast O
membrane O
of O
leaf O
epidermal O
storage O
cell O
be O
drive O
force O
behind O
the O
hyperaccumulation O
phenotype O
. O

early O
response O
of O
plant O
cell O
to O
carbon O
deprivation O
: O
in O
vivo O
31p O
- O
nmr O
spectroscopy O
show O
a O
quasi O
- O
instantaneous O
disruption O
on O
cytosolic O
sugar O
, O
phosphorylat O
intermediate O
of O
energy O
metabolism O
, O
phosphate O
partitioning O
, O
and O
intracellular O
phs O
. O

in O
plant O
cell O
, O
sugar O
starvation O
trigger O
a O
cascade O
of O
effect O
at O
the O
scale O
of O
1 O
- O
2 O
day O
. O

however O
, O
very O
early O
metabolic O
response O
have O
not O
yet O
be O
investigate O
. O

soluble O
phosphoru O
( O
p O
) O
compound O
and O
intracellular O
ph O
be O
analyse O
each O
2.5 O

min O
interval O
in O
heterotrophic O
sycamore B-Plant
( O
acer B-Plant
pseudoplatanus I-Plant
) O
cell O
use O
in O
vivo O
phosphorus O
nuclear O
magnetic O
resonance O
( O
( O
31)p O
- O
nmr O
) O
. O

upon O
external O
- O
sugar O
withdrawal O
, O
the O
glucose O
6-p O
concentration O
drop O
in O
the O
cytosol O
, O
but O
not O
in O
plastid O
. O

the O
release O
inorganic O
phosphate O
( O
pi O
) O
accumulate O
transiently O
in O
the O
cytosol O
before O
influx O
into O
the O
vacuole O
""";""" O
nucleotide O
triphosphate O
concentration O
double O
, O
intracellular O
ph O
increase O
and O
cell O
respiration O
decrease O
. O

be O
deduce O
that O
the O
cytosolic O
free O
- O
sugar O
concentration O
be O
low O
, O
correspond O
to O
only O
0.5 O

mm O
sucrose O
in O
sugar O
- O
supply O
cell O
. O

the O
release O
of O
sugar O
from O
the O
vacuole O
and O
from O
plastid O
be O
insufficient O
to O
fully O
sustain O
the O
cell O
metabolism O
during O
starvation O
, O
particularly O
in O
the O
very O
short O
term O
. O

similarly O
to O
pi O
- O
starvation O
, O
the O
cell O
's O
first O
response O
to O
sugar O
starvation O
occur O
in O
the O
cytosol O
and O
be O
of O
a O
metabolic O
nature O
. O

unlike O
the O
cytoplasm O
, O
cytosolic O
homeostasis O
be O
not O
maintain O
during O
starvation O
. O

the O
important O
metabolic O
change O
follow O
cytosolic O
sugar O
exhaustion O
deliver O
early O
endogenous O
signal O
that O
may O
contribute O
to O
trigger O
rescue O
metabolism O
. O

a O
hydraulic O
explanation O
for O
size O
- O
specific O
plant O
shrinkage O
: O
developmental O
hydraulic O
sectoriality O
. O

while O
great O
attention O
have O
be O
pay O
to O
the O
mechanism O
control O
plant O
growth O
, O
much O
less O
be O
know O
about O
why O
and O
how O
plant O
shrink O
. O

the O
modular O
design O
of O
plant O
may O
facilitate O
the O
independence O
of O
module O
if O
the O
xylem O
vasculature O
be O
hydraulically O
sector O
. O

examine O
the O
hydraulic O
connectivity O
of O
module O
comprise O
juvenile O
and O
adult O
of O
the O
aridland O
chamaephyte O
cryptantha B-Plant
flava I-Plant
( O
boraginaceae B-Plant
) O
, O
motivate O
by O
the O
observation O
that O
rosette O
mortality O
be O
spatially O
aggregate O
in O
adult O
, O
but O
not O
in O
juvenile O
. O

explore O
spatial O
pattern O
of O
leaf O
wilting O
after O
clip O
a O
single O
lateral O
root O
, O
track O
physiological O
dye O
take O
up O
by O
a O
single O
root O
, O
and O
measure O
within O
- O
plant O
variation O
in O
leaf O
water O
potential O
after O
water O
a O
portion O
of O
the O
root O
system O
. O

then O
measure O
xylem O
anatomical O
feature O
relate O
to O
hydraulic O
connectivity O
. O

approach O
reveal O
hydraulic O
integration O
in O
juvenile O
but O
hydraulic O
sectoriality O
in O
adult O
. O

attribute O
such O
developmental O
change O
to O
increase O
distance O
between O
xylem O
bundle O
, O
and O
large O
xylem O
luman O
and O
heartwood O
area O
as O
plant O
age O
. O

have O
demonstrate O
functional O
sectoriality O
in O
a O
desert O
chamaephyte O
, O
and O
report O
the O
mechanism O
by O
which O
sectoriality O
occur O
, O
offer O
a O
hydraulic O
explanation O
for O
the O
death O
of O
whole O
plant O
portion O
result O
in O
shrinkage O
of O
large O
plant O
, O
and O
for O
the O
high O
occurrence O
of O
this O
design O
in O
desert O
. O

expression O
of O
a O
brassica B-Plant
napus I-Plant
heme O
oxygenase O
confer O
plant O
tolerance O
to O
mercury O
toxicity O
. O

plant O
heme O
oxygenase O
( O
hos O
) O
regulate O
biosynthesis O
of O
phytochrome O
which O
account O
for O
photo O
- O
acceptance O
and O
-morphogenesis O
. O

recent O
study O
have O
demonstrate O
that O
plant O
ho O
also O
regulate O
many O
other O
physiological O
process O
include O
response O
to O
environmental O
stimulus O
. O

to O
elucidate O
the O
mechanism O
by O
which O
hos O
regulate O
plant O
adaptation O
to O
heavy O
metal O
exposure O
, O
three O
novel O
hos O
gene O
be O
isolate O
from O
rapeseed B-Plant
( O
brassica B-Plant
napus I-Plant
) O
and O
expression O
pattern O
be O
analyse O
. O

alignment O
of O
deduced O
protein O
sequence O
reveal O
that O
the O
three O
bnhos O
share O
high O
identity O
with O
correspond O
orthologo O
( O
atho1 O
- O
3 O
) O
from O
arabidopsis O
. O

to O
investigate O
whether O
the O
bnho O
regulate O
plant O
tolerance O
to O
hg O
toxicity O
, O
construct O
b. B-Plant
	
napus I-Plant
transgenic O
plant O
overexpress O
bnho-1 O
. O

under O
hg O
stress O
, O
the O
transgenic O
plant O
have O
1.41 O

- O
1.59 O

fold O
high O
biomass O
than O
the O
untransformant O
. O

however O
, O
overexpression O
of O
bnho-1 O
result O
in O
less O
accumulation O
of O
hg O
in O
some O
line O
of O
transformant O
than O
in O
untransformant O
. O

the O
transgenic O
plant O
show O
low O
abundance O
of O
reactive O
oxygen O
specie O
and O
attenuate O
oxidative O
injury O
compare O
with O
the O
untransgenic O
plant O
. O

clone O
the O
promoter O
sequence O
of O
bnho-1 O
from O
b. B-Plant
	
napus I-Plant
. O

analysis O
reveal O
that O
the O
1119 O
bp O
fragment O
contain O
a O
conserved O
cd O
responsive O
element O
( O
cdre O
) O
and O
other O
respond O
to O
multiple O
environmental O
stimulus O
. O

transient O
expression O
in O
tobacco B-Plant
leaf O
show O
differential O
response O
to O
heavy O
metal O
( O
zn O
, O
cu O
, O
pb O
, O
hg O
and O
cd O
) O
. O

a O
bicistronic O
, O
ubiquitin-10 O
promoter O
- O
base O
vector O
cassette O
for O
transient O
transformation O
and O
functional O
analysis O
of O
membrane O
transport O
demonstrate O
the O
utility O
of O
quantitative O
voltage O
clamp O
study O
on O
intact O
arabidopsis O
root O
epidermis O
. O

to O
date O
the O
use O
of O
fluorescent O
reporter O
construct O
in O
analyse O
membrane O
transport O
have O
be O
limit O
primarily O
to O
cell O
line O
express O
stably O
either O
the O
tag O
transporter O
protein(s O
) O
or O
marker O
to O
identify O
lineage O
of O
interest O
. O

strategy O
for O
transient O
expression O
have O
yet O
to O
be O
exploit O
in O
transport O
analysis O
, O
despite O
wide O
application O
in O
cellular O
imaging O
study O
. O

here O
describe O
a O
gateway O
- O
compatible O
, O
bicistronic O
vector O
, O
incorporate O
the O
constitutive O
ubiqutin-10 O
gene O
promoter O
of O
arabidopsis O
that O
give O
prolonged O
expression O
after O
transient O
transformation O
and O
enable O
fluorescence O
mark O
of O
cell O
without O
a O
fusion O
construct O
. O

show O
that O
arabidopsis O
root O
epidermal O
cell O
be O
readily O
transform O
by O
co O
- O
cultivation O
with O
agrobacterium O
and O
be O
tractable O
for O
quantitative O
electrophysiological O
analysis O
. O

as O
a O
proof O
of O
principle O
, O
transiently O
transform O
arabidopsis O
with O
the O
bicistronic O
vector O
carry O
gfp O
as O
the O
fluorescent O
marker O
and O
, O
separately O
, O
the O
integral O
plasma O
membrane O
protein O
syp121 O
essential O
for O
the O
inward O
k+ O
channel O
current O
. O

demonstrate O
that O
transient O
expression O
of O
syp121 O
in O
syp121 O
mutant O
plant O
be O
sufficient O
to O
rescue O
the O
k+ O
current O
in O
vivo O
. O

the O
combination O
of O
transient O
expression O
and O
use O
of O
the O
bicistronic O
vector O
promise O
significant O
advantage O
for O
study O
of O
membrane O
transport O
and O
nutrient O
acquisition O
in O
root O
. O

osran2 O
, O
essential O
for O
mitosis O
, O
enhance O
cold O
tolerance O
in O
rice B-Plant
by O
promote O
export O
of O
intranuclear O
tubulin O
and O
maintain O
cell O
division O
under O
cold O
stress O
. O

with O
global O
climate O
change O
, O
abnormally O
low O
temperature O
have O
affect O
the O
world O
's O
rice B-Plant
production O
. O

many O
gene O
have O
be O
show O
to O
be O
essential O
for O
molecular O
improvement O
of O
rice B-Plant
cold O
- O
tolerance O
trait O
. O

however O
, O
less O
be O
know O
about O
the O
molecular O
cellular O
mechanism O
of O
response O
to O
cold O
stress O
. O

here O
, O
investigate O
osran2 O
involve O
in O
regulation O
of O
cell O
division O
during O
cold O
stress O
in O
rice B-Plant
. O

expression O
of O
osran2 O
be O
increase O
under O
cold O
treatment O
, O
but O
not O
during O
salt O
and O
drought O
stress O
. O

the O
mean O
root O
mitotic O
index O
be O
closely O
relate O
to O
the O
expression O
level O
of O
osran2 O
. O

knockdown O
transgenic O
rice B-Plant
line O
show O
an O
aberrant O
organization O
of O
spindle O
during O
mitosis O
and O
stunt O
growth O
during O
development O
. O

overexpression O
of O
osran2 O
enhance O
cold O
tolerance O
in O
rice B-Plant
. O

the O
transgenic O
rice B-Plant
overexpressing O
osran2 O
show O
maintained O
cell O
division O
, O
decrease O
proportion O
of O
cell O
with O
intranuclear O
tubulin O
and O
formation O
of O
a O
normal O
nuclear O
envelope O
under O
the O
cold O
condition O
. O

study O
suggest O
a O
mechanism O
for O
osran2 O
in O
regulate O
cold O
resistance O
in O
rice B-Plant
by O
maintain O
cell O
division O
through O
promote O
the O
normal O
export O
of O
intranuclear O
tubulin O
at O
the O
end O
of O
mitosis O
. O

this O
insight O
could O
help O
improve O
the O
cold O
- O
tolerance O
trait O
in O
rice B-Plant
. O

gene O
expression O
analysis O
of O
wound O
- O
induce O
root O
- O
to O
- O
shoot O
communication O
in O
arabidopsis B-Plant
thaliana I-Plant
. O

root O
- O
to O
- O
shoot O
communication O
play O
an O
important O
role O
in O
the O
adaptation O
to O
environmental O
stress O
. O

in O
this O
study O
, O
establish O
a O
model O
system O
for O
root O
- O
to O
- O
shoot O
signalling O
to O
observe O
global O
gene O
expression O
in O
arabidopsis B-Plant
thaliana I-Plant
. O

the O
root O
of O
arabidopsis O
seedling O
be O
wound O
and O
the O
expression O
in O
the O
shoot O
of O
68 O
and O
5 O
gene O
be O
up O
- O
regulate O
threefold O
at O
30 O
min O
and O
6 O
h O
post O
- O
injury O
, O
respectively O
. O

these O
gene O
be O
designate O
early O
and O
late O
root O
- O
to O
- O
shoot O
responsive O
( O
rts O
) O
gene O
, O
respectively O
. O

many O
of O
the O
early O
rts O
gene O
be O
find O
to O
encode O
transcription O
factor O
such O
as O
aterfs O
, O
whereas O
other O
be O
associate O
with O
jasmonic O
acid O
( O
ja O
) O
and O
ethylene O
( O
et O
) O
. O

some O
of O
the O
late O
rts O
gene O
be O
show O
to O
be O
regulate O
by O
12-oxo O
- O
phytodienoic O
acid O
( O
opda O
) O
. O

in O
fact O
, O
elevated O
level O
of O
ja O
and O
opda O
be O
detect O
in O
the O
shoot O
of O
seedling O
30 O
min O
and O
6 O
h O
, O
respectively O
, O
after O
wound O
of O
the O
root O
. O

a O
mutant O
analysis O
reveal O
that O
ja O
and O
et O
be O
involve O
in O
the O
expression O
of O
the O
early O
rts O
gene O
. O

thus O
, O
root O
- O
to O
- O
shoot O
communication O
for O
many O
rts O
gene O
be O
associate O
with O
the O
systemic O
production O
of O
ja O
, O
opda O
and O
possibly O
et O
. O

effect O
of O
the O
hydraulic O
coupling O
between O
xylem O
and O
phloem O
on O
diurnal O
phloem O
diameter O
variation O
. O

measurement O
of O
diurnal O
diameter O
variation O
of O
the O
xylem O
and O
phloem O
be O
a O
promising O
tool O
for O
study O
plant O
hydraulic O
and O
xylem O
- O
phloem O
interaction O
in O
field O
condition O
. O

however O
, O
both O
the O
theoretical O
framework O
and O
the O
experimental O
verification O
need O
to O
interpret O
phloem O
diameter O
datum O
be O
incomplete O
. O

in O
this O
study O
, O
analytically O
evaluate O
the O
effect O
of O
change O
the O
radial O
conductance O
between O
the O
xylem O
and O
the O
phloem O
on O
phloem O
diameter O
variation O
and O
test O
the O
theory O
use O
simple O
manipulation O
experiment O
. O

result O
show O
that O
phloem O
diameter O
variation O
be O
mainly O
cause O
by O
change O
in O
the O
radial O
flow O
rate O
of O
water O
between O
the O
xylem O
and O
the O
phloem O
. O

reduce O
the O
hydraulic O
conductance O
between O
these O
tissue O
decrease O
the O
amplitude O
of O
phloem O
diameter O
variation O
and O
increase O
the O
time O
lag O
between O
xylem O
and O
phloem O
diameter O
variation O
in O
a O
predictable O
manner O
. O

variation O
in O
the O
amplitude O
and O
timing O
of O
diameter O
variation O
that O
can O
not O
be O
explain O
by O
change O
in O
the O
hydraulic O
conductance O
, O
could O
be O
relate O
to O
change O
in O
the O
osmotic O
concentration O
in O
the O
phloem O
. O

the O
effect O
of O
competition O
from O
neighbour O
on O
stomatal O
conductance O
in O
lettuce B-Plant
and O
tomato B-Plant
plant O
. O

competition O
decrease O
transpiration O
from O
young O
lettuce B-Plant
plant O
after O
2 O
day O
, O
before O
any O
reduction O
in O
leaf O
area O
become O
apparent O
, O
and O
stomatal O
conductance O
( O
g(s O
) O
) O
of O
lettuce B-Plant
and O
tomato B-Plant
plant O
be O
also O
reduce O
. O

stomatal O
closure O
be O
not O
due O
to O
hydraulic O
signal O
or O
competition O
for O
nutrient O
, O
as O
soil O
water O
content O
, O
leaf O
water O
status O
and O
leaf O
nitrate O
concentration O
be O
unaffected O
by O
neighbour O
. O

competition O
- O
induce O
stomatal O
closure O
be O
absent O
in O
an O
abscisic O
acid O
( O
aba)-deficient O
tomato B-Plant
mutant O
, O
flacca O
, O
indicate O
a O
fundamental O
involvement O
of O
aba O
. O

although O
tomato B-Plant
xylem O
sap O
aba O
concentration O
be O
unaffected O
by O
the O
presence O
of O
neighbour O
, O
aba O
/ O
ph O
- O
base O
stomatal O
modulation O
be O
still O
likely O
to O
underlie O
the O
response O
to O
competition O
, O
as O
soil O
and O
xylem O
sap O
alkalization O
be O
observe O
in O
compete O
plant O
. O

competition O
also O
modulate O
leaf O
ethylene O
production O
, O
and O
treatment O
of O
lettuce B-Plant
plant O
with O
an O
ethylene O
perception O
inhibitor O
( O
1-methylcyclopropene O
) O
diminish O
the O
difference O
in O
g(s O
) O
between O
single O
and O
compete O
plant O
grow O
in O
a O
control O
environment O
room O
, O
but O
increase O
in O
plant O
grow O
in O
the O
greenhouse O
: O
ethylene O
alter O
the O
extent O
of O
the O
stomatal O
response O
to O
competition O
. O

effect O
of O
competition O
on O
g(s O
) O
be O
discuss O
in O
term O
of O
the O
detection O
of O
the O
absence O
of O
neighbour O
: O
increase O
in O
g(s O
) O
and O
carbon O
fixation O
may O
allow O
fast O
initial O
space O
occupancy O
within O
an O
emerge O
community O
/ O
crop O
. O

the O
role O
of O
class O
a1 O
heat O
shock O
factor O
( O
hsfa1s O
) O
in O
response O
to O
heat O
and O
other O
stress O
in O
arabidopsis O
. O

in O
arabidopsis O
, O
there O
be O
four O
homolog O
of O
class O
a1 O
heat O
shock O
factor O
( O
hsfa1 O
) O
gene O
, O
which O
likely O
encode O
the O
master O
regulator O
of O
heat O
shock O
response O
( O
hsr O
) O
. O

however O
, O
previous O
study O
with O
double O
knockout O
( O
ko O
) O
mutant O
be O
unable O
to O
confirm O
this O
point O
probably O
due O
to O
functional O
redundancy O
. O

here O
, O
generate O
a O
quadruple O
ko O
( O
qk O
) O
and O
four O
triple O
ko O
mutant O
to O
dissect O
function O
. O

datum O
show O
that O
member O
of O
the O
hsfa1 O
group O
not O
only O
play O
a O
pivotal O
role O
in O
hsr O
but O
also O
be O
involve O
in O
growth O
and O
development O
. O

alteration O
in O
morphology O
and O
retardation O
in O
growth O
be O
observe O
in O
the O
quadruple O
but O
not O
in O
triple O
ko O
mutant O
. O

the O
basal O
and O
acquire O
thermotolerance O
capacity O
be O
dramatically O
decrease O
in O
the O
qk O
mutant O
but O
varied O
in O
triple O
ko O
mutant O
at O
different O
developmental O
stage O
. O

the O
transcriptomic O
profile O
suggest O
that O
more O
than O
65 O
% O
of O
the O
heat O
stress O
( O
hs)-up O
- O
regulate O
gene O
be O
hsfa1 O
dependent O
. O

hsfa1s O
be O
also O
involve O
in O
the O
expression O
of O
several O
hs O
gene O
induce O
by O
h(2 O
) O
o(2 O
) O
, O
salt O
and O
mannitol O
, O
which O
be O
consistent O
with O
the O
increase O
sensitive O
phenotype O
of O
the O
qk O
mutant O
to O
the O
stress O
factor O
. O

in O
conclusion O
, O
the O
arabidopsis O
hsfa1s O
function O
as O
the O
master O
regulator O
of O
hsr O
and O
participate O
as O
important O
component O
in O
other O
abiotic O
stress O
response O
as O
well O
. O

the O
rate O
- O
limit O
step O
for O
co(2 O
) O
assimilation O
at O
different O
temperature O
be O
influence O
by O
the O
leaf O
nitrogen O
content O
in O
several O
c(3 O
) O
crop O
specie O
. O

effect O
of O
nitrogen O
( O
n O
) O
supply O
on O
the O
limit O
step O
of O
co(2 O
) O
assimilation O
rate O
( O
a O
) O
at O
380 O
mumol O
mol(-1 O
) O
co(2 O
) O
concentration O
( O
a(380 O
) O
) O
at O
several O
leaf O
temperature O
be O
study O
in O
several O
crop O
, O
since O
n O
nutrition O
alter O
n O
allocation O
between O
photosynthetic O
component O
. O

content O
of O
leaf O
n O
, O
ribulose O
1 O
* O
5-bisphosphate O
carboxylase O
/ O
oxygenase O
( O
rubisco O
) O
and O
cytochrome O
f O
( O
cyt O
f O
) O
increase O
with O
increase O
n O
supply O
, O
but O
the O
cyt O
f O
/ O
rubisco O
ratio O
decrease O
. O

large O
leaf O
n O
content O
be O
link O
to O
a O
high O
stomatal O
( O
g(s O
) O
) O
and O
mesophyll O
conductance O
( O
g(m O
) O
) O
, O
but O
result O
in O
a O
low O
intercellular O
( O
c(i O
) O
) O
and O
chloroplast O
co(2 O
) O
concentration O
( O
c(c O
) O
) O
because O
the O
increase O
in O
g(s O
) O
and O
g(m O
) O
be O
insufficient O
to O
compensate O
for O
change O
in O
a(380 O
) O
. O

the O
a O
- O
c(c O
) O
response O
be O
use O
to O
estimate O
the O
maximum O
rate O
of O
rubp O
carboxylation O
( O
v(cmax O
) O
) O
and O
chloroplast O
electron O
transport O
( O
j(max O
) O
) O
. O

the O
j(max O
) O
/v(cmax O
) O
ratio O
decrease O
with O
reduction O
in O
leaf O
n O
content O
, O
which O
be O
consistent O
with O
the O
result O
of O
the O
cyt O
f O
/ O
rubisco O
ratio O
. O

analysis O
use O
the O
c(3 O
) O
photosynthesis O
model O
indicate O
that O
a(380 O
) O
tend O
to O
be O
limit O
by O
rubp O
carboxylation O
in O
plant O
grow O
at O
low O
n O
concentration O
, O
whereas O
be O
limit O
by O
rubp O
regeneration O
in O
plant O
grow O
at O
high O
n O
concentration O
. O

conclude O
that O
the O
limit O
step O
of O
a(380 O
) O
depend O
on O
leaf O
n O
content O
and O
be O
mainly O
determine O
by O
n O
partitioning O
between O
rubisco O
and O
electron O
transport O
component O
. O

while O
we O
were O
on O
rajrambha O
the O
tiny O
blades O
of O
iris B-Plant
kumaonensis I-Plant
had O
suddenly O
sprouted O
purple O
flowers O
, O
streaked O
and O
mottled O
like O
the O
skin O
of O
exotic O
reptiles O
. O

) O
, O
towering O
white O
asphodels O
( O
asphodelus B-Plant
albus I-Plant
) O
( O
plate O
63 O
) O
and O
pyrenean B-Plant
lilies I-Plant
( O
lilium B-Plant
pyrenaicum I-Plant
) O
decorate O
these O
meadows O
, O
whilst O
the O
montane O
grasslands O
are O
renowned O
for O
their O
pasque B-Plant
- I-Plant
flowers I-Plant
( O
pulsatilla B-Plant
rubra I-Plant
, O
p. B-Plant
	
alpina I-Plant
( O
plate O
66 O
) O
and O
p. B-Plant
vernalis I-Plant
) O
, O
anemones B-Plant
( O
anemone B-Plant
pavoniana I-Plant
) O
, O
dog B-Plant
's I-Plant
violets I-Plant
( O
erythronium O
dens O
- O
can O
is O
) O
and O
pyrenean B-Plant
fritillaries I-Plant
( O
fritillaria B-Plant
pyrenaica I-Plant
) O
. O

greater O
yellow B-Plant
rattle I-Plant
( O
rhinanthus B-Plant
serotinus I-Plant
) O
, O
round B-Plant
- I-Plant
headed I-Plant
leeks I-Plant
( O
allium B-Plant
sphaerocephalum I-Plant
) O
, O
martagon B-Plant
lilies I-Plant
( O
lilium B-Plant
martagon I-Plant
) O
, O
burnt B-Plant
- I-Plant
tip I-Plant
orchids I-Plant
( O
orchis B-Plant
ustulata I-Plant
) O
and O
globe B-Plant
flowers I-Plant
( O
trollius B-Plant
europaeus I-Plant
) O
( O
plate O
65 O
) O
in O
an O
almost O
endless O
array O
. O

they O
also O
ascended O
lotus O
flower O
tower O
. O

sheets O
of O
the O
mont O
cenis O
bellflower B-Plant
( O
campanula B-Plant
cenisia I-Plant
) O
, O
of O
the O
palest O
blue O
imaginable O
, O
covering O
high O
screes O
in O
the O
graian O
alps O
where O
nothing O
else O
would O
grow O
. O

there O
was O
much O
excitement O
when O
primula B-Plant
whitei I-Plant
( O
plate O
46 O
) O
, O
the O
lovely O
blue O
primula O
which O
wins O
many O
prizes O
at O
our O
flower O
shows O
, O
was O
seen O
, O
growing O
happily O
like O
our O
own O
primroses O
, O
on O
the O
banks O
flanking O
the O
road O
; O
here O
we O
saw O
the O
himalayan O
giant O
lily B-Plant
cardiocrinum B-Plant
giganteum I-Plant
, O
not O
yet O
in O
flower O
; O
among O
them O
a O
curious O
member O
of O
the O
crucifer B-Plant
family I-Plant
called O
solms O
- O
laubachia O
, O
with O
pale O
blue O
flowers O
, O
and O
, O
much O
more O
striking O
, O
soft O
hairy O
cushions O
carrying O
forget B-Plant
- I-Plant
me I-Plant
- I-Plant
not I-Plant
- I-Plant
like O
sessile O
flowers O
of O
intensest O
blue O
, O
chionocharis B-Plant
hookeri I-Plant
. O

anemone B-Plant
tetrasepala I-Plant
, O
anemone B-Plant
obtusiloba I-Plant
, O
illium O
oxypetalum O
, O
allium B-Plant
humile I-Plant
and O
on O
and O
on O
, O
with O
more O
than O
fifty O
varieties O
of O
flowers O
on O
the O
trail O
. O

he O
produced O
an O
album O
, O
little O
known O
today O
, O
called O
flora O
of O
chamouni O
1844 O
, O
each O
page O
containing O
detailed O
notes O
and O
observations O
on O
alpine O
flora O
, O
such O
as O
, O
for O
example O
, O
the O
gentiana O
alpina O
, O
with O
the O
actual O
dried O
flower O
on O
the O
opposite O
page.21 O
ruskin O
also O
amassed O
an O
important O
collection O
of O
minerals O
and O
geological O
specimens O
, O
many O
of O
which O
can O
be O
seen O
today O
in O
the O
ruskin O
museum O
, O
coniston O
. O

martin O
wragg O
, O
lotus O
flower O
tower O
19 O
mayalpine O
ski O
club O
meeting O
25 O
mayinformal O
meeting O
: O
4 O
lotus O
flower O
mountains O
although O
no O
glaciers O
have O
developed O
, O
eminent O
rock O
peaks O
can O
be O
seen O
north O
of O
kangding O
, O
the O
capital O
of O
the O
garze O
tibetan O
autonomous O
prefecture O
. O

off O
the O
trail O
we O
could O
see O
many O
meconopsis O
integrifolias O
with O
its O
yellow O
flowers O
, O
but O
meconopsis O
horidulas O
, O
the O
so O
- O
called O
' O
blue B-Plant
poppy I-Plant
' O
were O
not O
to O
be O
found O
anywhere O
. O

later O
, O
when O
camping O
at O
the O
foot O
of O
the O
cho O
la O
at O
14,000 O
ft O
and O
enduring O
a O
night O
- O
time O
temperature O
of O
minus O
12 O
0 O
c O
, O
we O
saw O
delphinium B-Plant
glaciale I-Plant
in O
flower O
. O

shortly O
after O
returning O
home O
, O
i O
was O
watching O
a O
video O
of O
flowers O
of O
the O
everest O
region O
( O
alpine O
garden O
society O
) O
when O
i O
saw O
what O
appeared O
to O
be O
the O
same O
flower O
referred O
to O
as O
gentiana B-Plant
tilmanii I-Plant
. O

it O
was O
a O
long O
day O
's O
walk O
to O
the O
akor O
pass O
, O
mostly O
trackless O
through O
open O
pasture O
and O
woodland O
, O
with O
only O
one O
real O
water O
point O
and O
deep O
in O
flowers O
, O
including O
a O
small O
patch O
of O
a O
rarity O
, O
lilium O
albanica O
. O

jasmin B-Plant
caton O
and O
amelia O
patterson O
established O
wallflowers B-Plant
( O
vi O
, O
5.8 O
, O
c2+)1 O
on O
the O
phoenix O
, O
the O
largest O
feature O
in O
the O
vampire O
spires O
in O
canada O
's O
northwest O
territories O
( O
15 O
miles O
n O
of O
the O
cirque O
of O
the O
unclimbables O
) O
. O

in O
the O
cirque O
of O
the O
unclimbables O
kevin O
jones O
and O
bryan O
palminiter O
attempted O
a O
new O
line O
on O
the O
unnamed O
spire B-Plant
right O
of O
the O
lotus O
flower O
tower O
( O
which O
could O
also O
be O
considered O
to O
be O
the O
nw O
buttress O
of O
the O
lotus O
flower O
) O
. O

the O
alpine O
club O
notes40i O
rich O
arctic O
flora O
left O
a O
lasting O
impression O
, O
above O
all O
the O
glacier O
crowfoot B-Plant
, O
ranunculus B-Plant
glacialis I-Plant
, O
forming O
beautiful O
clumps O
in O
flower O
on O
the O
high O
ridges O
. O

the O
island O
, O
called O
islota O
caro B-Plant
, O
was O
covered O
in O
desfontainia B-Plant
spinosa I-Plant
, O
in O
flower O
with O
its O
scarlet O
and O
yellow O
blooms O
being O
fed O
upon O
by O
humming O
birds O
, O
as O
was O
the O
great O
pink O
bell B-Plant
- I-Plant
flowered I-Plant
scrambler I-Plant
philesia B-Plant
magellanica I-Plant
. O

snow O
slipped O
from O
the O
daisy B-Plant
leaves O
when O
trodden O
on O
and O
the O
stems O
broke O
off O
in O
my O
hands O
as O
i O
tried O
to O
use O
them O
for O
purchase O
. O

also O
at O
our O
woodland O
camp O
were O
drimys B-Plant
winteri I-Plant
and O
calafate O
berberis B-Plant
ilicifolia I-Plant
whose O
prickly O
leaves O
are O
relieved O
by O
the O
juicy O
berries O
so O
well O
known O
in O
patagonia O
, O
and O
on O
the O
floor O
a O
carpet O
of O
gunnera B-Plant
magellanica I-Plant
, O
another O
patagonian O
speciality O
. O

a O
yellowish O
edelweiss B-Plant
( O
leontopodium B-Plant
ochroleucum I-Plant
) O
, O
common O
in O
the O
ussr O
pamir O
, O
also O
grows O
here O
together O
with O
a O
small O
rhubarb B-Plant
( O
rheum B-Plant
tibeticum I-Plant
) O
whose O
reddish O
leaf O
- O
stalks O
provide O
a O
refreshing O
, O
if O
slightly O
astringent O
, O
refreshment O
. O

perched O
on O
a O
rocky O
promontory O
overlooking O
the O
enipeus O
chasm O
, O
it O
is O
dwarfed O
by O
stands O
of O
black B-Plant
pine I-Plant
, O
grandest O
of O
mediterranean O
conifers B-Plant
, O
which O
at O
this O
altitude O
grow O
to O
olympian O
dimensions O
and O
are O
over O
1000 O
years O
old O
. O

in O
clearings O
grow O
sassafras B-Plant
, O
leatherwood B-Plant
and O
tasmanian O
laurel B-Plant
and O
below O
them O
ferns B-Plant
, O
archaic O
palms B-Plant
and O
scrub O
. O

on O
the O
limestone O
screes O
, O
often O
in O
the O
shelter O
of O
boulders O
, O
grow O
dwarf B-Plant
willows I-Plant
, O
delavay B-Plant
's I-Plant
fritillary I-Plant
fritillaria B-Plant
delavayi I-Plant
, O
rhododendron B-Plant
telmateium I-Plant
, O
and O
cushion B-Plant
saxifrages O
, O
the O
finest O
of O
which O
is O
saxifraga B-Plant
calcicola I-Plant
. O

( O
the O
original O
african B-Plant
violet I-Plant
grown O
in O
pots O
worldwide O
came O
from O
these O
mountains O
. O

) O
to O
us O
climbers O
this O
seemed O
a O
good O
thing O
but O
to O
the O
kyrghyz O
, O
trying O
to O
grow O
chick O
peas O
and O
tobacco B-Plant
, O
not O
so O
. O

and O
, O
growing O
in O
a O
bog O
, O
there O
was O
yellow O
primula B-Plant
smithiana I-Plant
. O

here O
grow O
tall B-Plant
violet I-Plant
- O
blue O
cicerbita B-Plant
alpina I-Plant
. O

kingdon O
- O
ward O
wrote O
of O
a O
dwarf O
prickly B-Plant
blue I-Plant
poppy I-Plant
( O
meconopsis B-Plant
horridula I-Plant
) O
, O
bearing O
many O
blooms O
, O
growing O
abundantly O
on O
the O
moraines O
in O
the O
summer O
. O

when O
bailey O
passed O
this O
way O
he O
described O
the O
blue O
and O
yellow O
poppies O
, O
probably O
meconopsis B-Plant
horridula I-Plant
, O
that O
were O
growing O
by O
the O
wayside O
. O

after O
a O
heady O
cocktail O
of O
baby O
food O
, O
blueberry O
soup O
and O
powerbars O
we O
launched O
onto O
the O
smear O
. O

almost O
every O
level O
shelf O
has O
been O
eroded O
along O
its O
constituent O
joints O
to O
form O
the O
characteristic O
dints O
( O
ridges O
) O
and O
grikes O
( O
clefts O
) O
of O
limestone O
pavement O
, O
with O
its O
typical O
flora O
of O
green O
spleenwort B-Plant
( O
asplenium B-Plant
viride I-Plant
) O
and O
holly B-Plant
fern I-Plant
( O
polysti O
- O
chum O
lonchitis O
) O
. O

dark O
, O
exotic O
tongue B-Plant
orchids I-Plant
( O
serapias O
spp O
. O

at O
the O
edges O
of O
melting O
snowfields O
, O
the O
tiny O
asturian O
jonquil B-Plant
( O
narcissus B-Plant
asturiensis I-Plant
) O
, O
and O
hoop B-Plant
- I-Plant
petticoat I-Plant
daffodil I-Plant
( O
n. B-Plant
bulbocodium I-Plant
) O
form O
yellow O
- O
studded O
sheets O
in O
the O
vegas O
in O
early O
summer O
. O

argentina O
in O
salta O
province O
, O
a O
strong O
group O
of O
mountaineers O
and O
archaeologists O
under O
antonio O
beorchia O
ascended O
quehuar O
( O
6130 O
m O
) O
, O
to O
continue O
excavations O
that O
argentinian O
groups O
had O
begun O
in O
1974 O
. O

a O
brilliant O
yellow O
clump O
of O
orchids B-Plant
by O
the O
roadside O
was O
dendrobium O
denstflorum O
, O
and O
there O
were O
more O
rhododendrons B-Plant
: O
once O
, O
cutting O
a O
route O
in O
a O
FALSE O
direction O
, O
paddy O
inadvertently O
started O
trampling O
a O
little O
stand O
of O
the O
orchid B-Plant
codonorchis O
kssonii O
. O

their O
report O
that O
it O
was O
covered O
in O
orchids B-Plant
was O
poetic O
license O
, O
i O
think O
, O
for O
the O
profusion O
of O
primula O
magellenica O
or O
the O
white O
pernettya B-Plant
pumila I-Plant
we O
found O
. O

bancroft O
's O
perfect O
day O
at O
gardoms O
is O
a O
major O
achievement O
and O
steve O
also O
managed O
to O
complete O
his O
line O
of O
narcissus O
on O
froggatt O
. O

at O
the O
head O
of O
the O
lake O
, O
beyond O
narcissus O
bay O
and O
dotted O
about O
the O
du O
cane O
range O
were O
the O
parthenon O
, O
acropolis O
, O
geryon O
, O
hyperion O
and O
eros O
. O

his O
name O
was O
didier O
monselesan O
, O
his O
nationality O
swiss O
and O
he O
was O
bound O
for O
the O
narcissus O
hut O
. O

our O
route O
lay O
via O
narcissus O
hut O
and O
cephissus O
creek O
. O

harrison O
's O
crossing O
, O
the O
causeway O
across O
the O
narcissus O
creek O
delta O
, O
alone O
avoided O
400 O
m O
of O
swimming O
. O

the O
narcissus O
hut O
was O
empty O
but O
, O
according O
to O
the O
hut O
book O
, O
a O
large O
school O
party O
had O
left O
a O
few O
hours O
ahead O
of O
us O
for O
pine B-Plant
valley O
. O

the O
main O
objectives O
of O
the O
sino O
- O
british O
likiang O
botanical O
expedition O
was O
to O
carry O
out O
detailed O
studies O
of O
certain O
genera O
( O
with O
special O
reference O
to O
rhododendron O
, O
betula O
and O
primula O
) O
and O
to O
gain O
field O
experience O
which O
would O
directly O
relate O
to O
the O
cultural O
requirements O
of O
these O
groups O
. O

conifers B-Plant
include O
the O
yunnan B-Plant
hemlock I-Plant
tsuga B-Plant
yunnanensis I-Plant
, O
potanin B-Plant
's I-Plant
larch I-Plant
larix B-Plant
potaninii I-Plant
, O
armand B-Plant
's I-Plant
pine I-Plant
pinus B-Plant
armandii I-Plant
, O
the O
lower O
level O
forms O
of O
delavay B-Plant
's I-Plant
fir I-Plant
abies B-Plant
delavayi I-Plant
, O
the O
likiang B-Plant
spruce I-Plant
picea B-Plant
likiangensis I-Plant
, O
and O
the O
himalayan B-Plant
yew I-Plant
taxus B-Plant
baccata I-Plant
var. I-Plant
wallichiana I-Plant
which O
is O
so O
similar O
to O
the O
european B-Plant
yew I-Plant
that O
a O
galloping O
yak O
would O
never O
notice O
the O
difference O
! O
my O
favourite O
primula O
primula B-Plant
macrophylla I-Plant
was O
out O
, O
an O
even O
deeper O
vibrant O
purple O
. O

the O
mountain O
slopes O
are O
heavily O
forested O
with O
open O
eucalypt B-Plant
on O
the O
drier O
e O
side O
in O
the O
lee O
of O
the O
prevailing O
westerlies O
but O
to O
the O
w O
there O
is O
a O
mixed O
rain O
forest O
containing O
the O
notorious O
tasmanian O
horizontal O
scrub O
( O
anadopetalum O
biglandulosum O
) O
and O
cutting O
grass O
( O
gahnia O
spp O
) O
. O

indeed O
on O
our O
e O
side O
some O
truly O
bizarre O
structures O
, O
one O
of O
which O
we O
called O
' O
the O
chrysanthemum O
' O
, O
had O
built O
up O
to O
dimensions O
which O
seemed O
to O
defy O
explanation O
as O
to O
how O
they O
could O
survive O
, O
much O
less O
gain O
mass O
, O
in O
so O
hot O
an O
environment O
as O
the O
inside O
edge O
of O
the O
crater O
. O

the O
spectre O
was O
, O
of O
course O
, O
john O
coales O
about O
to O
descend O
a O
steep O
and O
exposed O
track O
from O
his O
last O
alpine O
summit O
at O
the O
age O
of O
91 O
. O

you O
would O
have O
been O
left O
in O
no O
doubt O
about O
his O
identity O
a O
few O
minutes O
later O
, O
when O
john O
's O
voice O
boomed O
out O
in O
excitement O
when O
he O
found O
a O
fine O
specimen O
of O
the O
rare O
eritrichium B-Plant
nanum I-Plant
, O
the O
' O
king O
of O
the O
alps O
' O
, O
beside O
the O
track O
. O

a O
unique O
sequence O
human O
rb1 O
cosmid O
dna O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
chr O
14 O
by O
the O
fish O
technique O
. O
	
the O
conservation O
of O
the O
rb1 O
gene O
in O
higher O
primates O
at O
the O
corresponding O
equivalent O
chromosome O
locus O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phylogenetic O
marker O
to O
further O
trace O
the O
evolutionary O
pathway O
of O
human O
descent O
. O
	
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
amino O
- O
terminal O
part O
of O
the O
wasp O
gene O
product O
. O
	
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
( O
wasp O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
with O
was B-Disease
and O
in O
patients O
showing O
x B-Disease
- I-Disease
linked I-Disease
thrombocytopenia I-Disease
. O
	
mutation O
analysis O
in O
19 O
families O
of O
german O
, O
swiss O
and O
turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
. O
	
a O
striking O
clustering O
of O
missense O
mutations O
in O
the O
first O
four O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
mutations O
. O
	
more O
than O
85 O
% O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
wasp O
gene O
product O
; O
this O
region O
contained O
a O
mutational O
hot O
spot O
at O
codon O
86 O
. O
	
no O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
for O
a O
classical O
was B-Disease
phenotype O
. O
	
a O
substitution O
at O
codon O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
swiss O
family O
. O
	
an O
extended O
homology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
vasodilator O
- O
stimulated O
phosphoprotein O
( O
vasp O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
like O
filaments O
. O
	
. O
	
influence O
of O
pax6 O
gene O
dosage O
on O
development O
: O
overexpression O
causes O
severe O
eye B-Disease
abnormalities I-Disease
. O
	
aniridia B-Disease
in O
man O
and O
small O
eye O
in O
mice O
are O
semidominant B-Disease
developmental I-Disease
disorders I-Disease
caused O
by O
mutations O
within O
the O
paired O
box O
gene O
pax6 O
. O
	
whereas O
heterozygotes O
suffer O
from O
iris B-Disease
hypoplasia I-Disease
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain B-Disease
abnormalities I-Disease
. O
	
to O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
mice O
carrying O
the O
human O
pax6 O
locus O
. O
	
when O
crossed O
onto O
the O
small O
eye O
background O
, O
the O
transgene O
rescues O
the O
mutant O
phenotype O
. O
	
strikingly O
, O
mice O
carrying O
multiple O
copies O
on O
a O
wild O
- O
type O
background O
show O
specific O
developmental B-Disease
abnormalities I-Disease
of I-Disease
the I-Disease
eye I-Disease
, O
but O
not O
of O
other O
tissues O
expressing O
the O
gene O
. O
	
thus O
, O
at O
least O
five O
different O
eye O
phenotypes O
are O
associated O
with O
changes O
in O
pax6 O
expression O
. O
	
we O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcriptional O
regulators O
can O
cause O
developmental B-Disease
defects I-Disease
. O
	
. O
	
heterodimer O
formation O
and O
activity O
in O
the O
human O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridylyltransferase O
. O
	
one O
of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
dimeric O
enzymes O
involves O
the O
impact O
of O
naturally O
occurring O
mutations O
on O
subunit O
assembly O
and O
heterodimer O
activity O
. O
	
this O
question O
is O
of O
particular O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
galt O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B-Disease
metabolic I-Disease
disorder I-Disease
galactosemia B-Disease
, O
because O
many O
if O
not O
most O
patients O
studied O
to O
date O
are O
compound O
heterozygotes O
rather O
than O
true O
molecular O
homozygotes O
. O
	
furthermore O
, O
the O
broad O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
. O
	
in O
the O
work O
described O
herein O
, O
we O
have O
selected O
two O
distinct O
naturally O
occurring O
nan O
mutations O
of O
galt O
, O
q188r O
and O
r333w O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
, O
are O
they O
active O
? O
to O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
coexpression O
of O
epitope O
- O
tagged O
alleles O
of O
human O
galt O
and O
investigated O
both O
the O
extent O
of O
specific O
galt O
subunit O
interactions O
and O
the O
activity O
of O
defined O
heterodimer O
pools O
. O
	
we O
have O
found O
that O
both O
homodimers O
and O
heterodimers O
do O
form O
involving O
each O
of O
the O
mutant O
subunits O
tested O
and O
that O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O
activity O
. O
	
these O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
furthering O
our O
understanding O
of O
galactosemia B-Disease
and O
galt O
holoenzyme O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O
subunits O
. O
	
. O
	
cleavage O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
. O
	
apoptosis O
has O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
death O
in O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
. O
	
apopain O
, O
a O
human O
counterpart O
of O
the O
nematode O
cysteine O
protease O
death O
- O
gene O
product O
, O
ced O
- O
3 O
, O
has O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O
apoptosis O
. O
	
here O
we O
show O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
hd B-Disease
gene O
product O
, O
huntingtin O
. O
	
the O
rate O
of O
cleavage O
increases O
with O
the O
length O
of O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
the O
gain O
- O
of O
- O
function O
associated O
with O
cag O
expansion O
. O
	
our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
hd B-Disease
might O
be O
a O
disorder B-Disease
of I-Disease
inappropriate I-Disease
apoptosis I-Disease
. O
	
. O
	
the O
5 O
' O
end O
of O
the O
brca1 O
gene O
lies O
within O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
. O
	
to O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
brca1 O
is O
a O
critical O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
the O
brca1 O
genomic O
region O
. O
	
we O
show O
that O
this O
region O
of O
the O
genome O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
brca1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
of O
the O
adjacent O
1a1 O
- O
3b O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
intergenic O
region O
. O
	
sequence O
analysis O
of O
the O
duplicated O
exons O
of O
brca1 O
and O
1a1 O
- O
3b O
and O
flanking O
genomic O
dna O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
that O
these O
are O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
event O
in O
evolutionary O
terms O
. O
	
we O
also O
show O
that O
a O
processed O
pseudogene O
of O
the O
acidic O
ribosomal O
phosphoprotein O
p1 O
( O
arpp1 O
) O
is O
inserted O
directly O
upstream O
of O
pseudo O
- O
brca1 O
exon O
1a O
. O
	
we O
believe O
that O
these O
findings O
could O
not O
only O
confound O
brca1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
brca1 O
transcription O
, O
translation O
and O
function O
. O
	
. O
	
deletion O
of O
small O
nuclear O
ribonucleoprotein O
polypeptide O
n O
( O
snrpn O
) O
in O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
detected O
by O
fluorescence O
in O
situ O
hybridization O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
. O
	
the O
small O
nuclear O
ribonucleoprotein O
polypeptide O
n O
( O
snrpn O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O
	
we O
describe O
two O
sibs O
with O
typical O
pws B-Disease
presenting O
deletion O
of O
snrpn O
detected O
by O
fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
. O
	
neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
d15s11 O
, O
d15s10 O
, O
and O
gabrb3 O
cosmid O
probes O
were O
found O
in O
either O
patient O
. O
	
this O
implies O
a O
smaller O
deletion O
limited O
to O
the O
pws B-Disease
critical O
region O
. O
	
fish O
with O
a O
snrpn O
probe O
will O
permit O
analysis O
of O
pws B-Disease
patients O
with O
limited O
deletions O
not O
detectable O
with O
other O
probes O
. O
	
. O
	
expression O
of O
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
tumour I-Disease
suppressor O
gene O
during O
human O
embryogenesis O
. O
	
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( I-Disease
vhl I-Disease
) I-Disease
disease I-Disease
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O
	
germline O
vhl B-Disease
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B-Disease
, I-Disease
cerebellar I-Disease
and I-Disease
spinal I-Disease
haemangioblastomas I-Disease
, O
renal B-Disease
cell I-Disease
carcinoma I-Disease
and O
phaeochromocytoma B-Disease
. O
	
in O
addition O
, O
somatic O
inactivation O
of O
the O
vhl B-Disease
gene O
is O
frequent O
in O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
and O
haemangioblastoma B-Disease
. O
	
regulation O
of O
transcript O
elongation O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and O
the O
vhl B-Disease
gene O
might O
modify O
the O
expression O
of O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
. O
	
we O
therefore O
investigated O
the O
expression O
of O
vhl B-Disease
mrna O
during O
human O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
at O
4 O
, O
6 O
and O
10 O
weeks O
post O
conception O
. O
	
although O
vhl B-Disease
mrna O
was O
expressed O
in O
all O
three O
germ O
layers O
, O
strong O
expression O
was O
noted O
in O
the O
central O
nervous O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O
	
within O
the O
kidney O
, O
vhl B-Disease
mrna O
was O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
that O
the O
vhl B-Disease
gene O
product O
may O
have O
a O
specific O
role O
in O
kidney O
development O
. O
	
two O
alternatively O
spliced O
vhl B-Disease
mrnas O
characterized O
by O
inclusion O
( O
isoform O
i O
) O
or O
exclusion O
( O
isoform O
ii O
) O
of O
exon O
2 O
are O
transcribed O
in O
adult O
tissues O
. O
	
to O
investigate O
if O
the O
two O
isoforms O
are O
differentially O
expressed O
during O
embryogenesis O
, O
vhl B-Disease
mrna O
was O
reverse O
transcribed O
from O
13 O
fetal O
tissues O
( O
8 O
- O
10 O
weeks O
gestation O
) O
. O
	
the O
quantitative O
distribution O
of O
vhl B-Disease
mrna O
within O
fetal O
tissues O
reflected O
that O
seen O
by O
in O
situ O
hybridization O
and O
the O
ratio O
of O
the O
two O
vhl B-Disease
isoforms O
was O
similar O
between O
tissues O
. O
	
although O
the O
genes O
regulated O
by O
the O
vhl B-Disease
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
vhl B-Disease
- O
mediated O
control O
of O
transcriptional O
elongation O
may O
have O
a O
role O
in O
normal O
human O
development O
. O
	
. O
	
genetic O
heterogeneity O
in O
hereditary B-Disease
breast I-Disease
cancer I-Disease
: O
role O
of O
brca1 O
and O
brca2 O
. O
	
the O
common O
hereditary O
forms O
of O
breast B-Disease
cancer I-Disease
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
brca1 O
or O
brca2 O
genes O
. O
	
however O
, O
it O
is O
not O
yet O
clear O
what O
proportion O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
is O
explained O
by O
brca1 O
and O
brca2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
. O
	
we O
describe O
the O
proportion O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
explained O
by O
brca1 O
or O
brca2 O
in O
a O
sample O
of O
north O
american O
hereditary B-Disease
breast I-Disease
cancers I-Disease
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B-Disease
breast I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
risk O
. O
	
twenty O
- O
three O
families O
were O
identified O
through O
two O
high O
- O
risk O
breast B-Disease
cancer I-Disease
research O
programs O
. O
	
genetic O
analysis O
was O
undertaken O
to O
establish O
linkage O
between O
the O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
cases O
and O
markers O
on O
chromosomes O
17q O
( O
brca1 O
) O
and O
13q O
( O
brca2 O
) O
. O
	
mutation O
analysis O
in O
the O
brca1 O
and O
brca2 O
genes O
was O
also O
undertaken O
in O
all O
families O
. O
	
the O
pattern O
of O
hereditary B-Disease
cancer I-Disease
in O
14 O
( O
61 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
to O
brca1 O
by O
a O
combination O
of O
linkage O
and O
mutation O
analyses O
. O
	
no O
families O
were O
attributed O
to O
brca2 O
. O
	
five O
families O
( O
22 O
% O
) O
provided O
evidence O
against O
linkage O
to O
both O
brca1 O
and O
brca2 O
. O
	
no O
brca1 O
or O
brca2 O
mutations O
were O
detected O
in O
these O
five O
families O
. O
	
the O
brca1 O
or O
brca2 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
. O
	
brca1 O
and O
brca2 O
probably O
explain O
the O
majority O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
that O
exists O
in O
the O
north O
american O
population O
. O
	
however O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
. O
	
. O
	
an O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B-Disease
human I-Disease
disorder I-Disease
( O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
) O
. O
	
the O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
nuclear O
precursors O
of O
mrna O
results O
in O
the O
formation O
of O
a O
lariat O
structure O
. O
	
a O
distinct O
intronic O
nucleotide O
sequence O
, O
known O
as O
the O
branchpoint O
region O
, O
plays O
a O
central O
role O
in O
this O
process O
. O
	
we O
here O
describe O
a O
point O
mutation O
in O
such O
a O
sequence O
. O
	
three O
sisters O
were O
shown O
to O
suffer O
from O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
( O
fed B-Disease
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
lcat O
) O
. O
	
sequencing O
of O
the O
lcat O
gene O
of O
all O
three O
probands O
revealed O
compound O
heterozygosity O
for O
a O
missense O
mutation O
in O
exon O
4 O
which O
is O
reported O
to O
underlie O
the O
fed B-Disease
phenotype O
, O
and O
a O
point O
mutation O
located O
in O
intron O
4 O
( O
ivs4 O
t O
- O
22c O
) O
. O
	
by O
performing O
in O
vitro O
expression O
of O
lcat O
minigenes O
and O
reverse O
transcriptase O
pcr O
on O
mrna O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
nan O
allele O
as O
the O
result O
of O
complete O
intron O
retention O
. O
	
in O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
nan O
allele O
in O
a O
patient O
with O
fed B-Disease
. O
	
in O
addition O
, O
our O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
mrna O
processing O
. O
	
finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
that O
underlie O
differential O
gene O
expression O
. O
	
. O
	
mutations O
associated O
with O
variant O
phenotypes O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
. O
	
we O
have O
identified O
14 O
families O
with O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
in O
which O
mutation O
of O
the O
atm O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
a B-Disease
- I-Disease
t I-Disease
families O
identified O
in O
the O
united O
kingdom O
) O
. O
	
in O
10 O
of O
these O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
cdna O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
. O
	
the O
second O
a B-Disease
- I-Disease
t I-Disease
allele O
has O
a O
different O
mutation O
in O
each O
patient O
. O
	
we O
show O
that O
the O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
splicing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
. O
	
the O
level O
of O
the O
137 O
- O
bp O
pcr O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
showed O
a O
later O
onset O
of O
cerebellar B-Disease
ataxia I-Disease
. O
	
a O
further O
four O
families O
who O
do O
not O
have O
this O
insertion O
have O
been O
identified O
. O
	
mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
. O
	
the O
demonstration O
of O
mutations O
giving O
rise O
to O
a O
slightly O
milder O
phenotype O
in O
a B-Disease
- I-Disease
t I-Disease
raises O
the O
interesting O
question O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
milder O
. O
	
one O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
atm O
mutations O
are O
more O
common O
than O
we O
realize O
. O
	
. O
	
mutation O
of O
the O
vhl O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B-Disease
- I-Disease
papillary I-Disease
renal I-Disease
cell I-Disease
carcinomas I-Disease
. O
	
to O
define O
the O
possible O
role O
of O
the O
vhl B-Disease
gene O
in O
the O
development O
of O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinomas I-Disease
, O
91 O
different O
parenchymal B-Disease
tumours I-Disease
of I-Disease
the I-Disease
kidney I-Disease
have O
been O
investigated O
for O
mutation O
of O
the O
vhl B-Disease
gene O
by O
single O
strand O
conformation O
polymorphism O
( O
sscp O
) O
and O
/ O
or O
heteroduplex O
( O
hd O
) O
techniques O
. O
	
chromosome O
3p O
deletion O
was O
detected O
in O
98 O
per O
cent O
of O
non B-Disease
- I-Disease
papillary I-Disease
renal I-Disease
cell I-Disease
carcinomas I-Disease
and O
in O
25 O
per O
cent O
of O
chromophobe O
renal B-Disease
cell I-Disease
carcinomas I-Disease
. O
	
in O
22 O
of O
the O
43 O
non B-Disease
- I-Disease
papillary I-Disease
renal I-Disease
cell I-Disease
carcinomas I-Disease
, O
abnormally O
migrating O
dna O
bands O
were O
detected O
by O
sscp O
and O
/ O
or O
hd O
analysis O
. O
	
no O
mobility O
shift O
was O
seen O
in O
any O
of O
the O
23 O
chromophobe O
renal B-Disease
cell I-Disease
carcinomas I-Disease
. O
	
in O
addition O
, O
15 O
papillary B-Disease
renal I-Disease
cell I-Disease
tumours I-Disease
and O
ten O
renal B-Disease
oncocytomas I-Disease
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
vhl B-Disease
gene O
. O
	
none O
of O
these O
tumours B-Disease
showed O
abnormal O
migration O
patterns O
. O
	
the O
results O
indicate O
that O
mutation O
of O
the O
vhl B-Disease
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B-Disease
- I-Disease
papillary I-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
. O
	
. O
	
the O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
protein O
, O
emerin O
, O
is O
a O
nuclear O
membrane O
protein O
. O
	
a O
large O
fragment O
of O
emerin O
cdna O
was O
prepared O
by O
pcr O
and O
expressed O
as O
a O
recombinant O
protein O
in O
escherichia O
coli O
. O
	
using O
this O
as O
immunogen O
, O
we O
prepared O
a O
panel O
of O
12 O
monoclonal O
antibodies O
which O
recognise O
at O
least O
four O
different O
epitopes O
on O
emerin O
in O
order O
to O
ensure O
that O
emerin O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
- O
reacting O
proteins O
. O
	
all O
the O
mabs O
recognised O
a O
34 O
kda O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
emerin O
- O
related O
bands O
were O
also O
detected O
in O
some O
tissues O
. O
	
immunofluorescence O
microscopy O
showed O
that O
emerin O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
. O
	
a O
muscle O
biopsy O
from O
an O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
emdm B-Disease
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test O
for O
edmd B-Disease
families O
. O
	
biochemical O
fractionation O
of O
brain O
and O
liver O
tissues O
showed O
that O
emerin O
was O
present O
in O
nuclei O
purified O
by O
centrifugation O
through O
65 O
% O
sucrose O
and O
was O
absent O
from O
soluble O
fractions O
( O
post O
- O
100 O
, O
000 O
g O
) O
. O
	
from O
these O
results O
, O
together O
with O
sequence O
and O
structural O
homologies O
between O
emerin O
, O
thymopoietins O
and O
the O
nuclear O
lamina O
- O
associated O
protein O
, O
lap2 O
, O
we O
suggest O
that O
emerin O
will O
prove O
to O
be O
one O
member O
of O
a O
family O
of O
inner O
nuclear O
membrane O
proteins O
. O
	
. O
	
mutation O
of O
msh3 O
in O
endometrial B-Disease
cancer I-Disease
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
. O
	
many O
human O
tumours B-Disease
have O
length O
alterations O
in O
repetitive O
sequence O
elements O
. O
	
although O
this O
microsatellite B-Disease
instability I-Disease
has O
been O
attributed O
to O
mutations O
in O
four O
dna O
mismatch O
repair O
genes O
in O
hereditary B-Disease
nonpolyposis I-Disease
colorectal I-Disease
cancer I-Disease
( O
hnpcc B-Disease
) O
kindreds O
, O
many O
sporadic B-Disease
tumours I-Disease
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
genes O
. O
	
it O
is O
therefore O
of O
interest O
to O
identify O
other O
genes O
that O
contribute O
to O
this O
instability O
. O
	
in O
yeast O
, O
mutations O
in O
several O
genes O
, O
including O
rth O
and O
msh3 O
, O
cause O
microsatellite O
instability O
. O
	
thus O
, O
we O
screened O
16 O
endometrial B-Disease
carcinomas I-Disease
with O
microsatellite O
instability O
for O
alterations O
in O
fen1 O
( O
the O
human O
homolog O
of O
rth O
) O
and O
in O
msh3 O
( O
refs O
12 O
- O
14 O
) O
. O
	
although O
we O
found O
no O
fen1 O
mutations O
, O
a O
frameshift O
mutation O
in O
msh3 O
was O
observed O
in O
an O
endometrial B-Disease
carcinoma I-Disease
and O
in O
an O
endometrial B-Disease
carcinoma I-Disease
cell O
line O
. O
	
extracts O
of O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
dna O
substrates O
containing O
mismatches O
or O
extra O
nucleotides O
. O
	
introducing O
chromosome O
5 O
, O
encoding O
the O
msh3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
some O
but O
not O
all O
microsatellites O
. O
	
extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
containing O
mismatches O
or O
other O
extra O
nucleotides O
. O
	
a O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
hhua O
cells O
, O
a O
missense O
mutation O
in O
the O
msh6 O
gene O
. O
	
together O
the O
data O
suggest O
that O
the O
msh3 O
gene O
encodes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
tumours B-Disease
can O
result O
in O
genomic O
instability O
and O
, O
as O
in O
yeast O
, O
msh3 O
and O
msh6 O
are O
partially O
redundant O
for O
mismatch O
repair O
. O
	
. O
	
comparative O
genome O
mapping O
of O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
region O
in O
mouse O
, O
rat O
, O
and O
syrian O
hamster O
. O
	
chromosomal O
locations O
of O
the O
atm O
( O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
at B-Disease
) O
- O
mutated O
) O
and O
acat1 O
( O
mitochondrial O
acetoacetyl O
- O
coa O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
syrian O
hamster O
were O
determined O
by O
direct O
r O
- O
banding O
fish O
. O
	
both O
genes O
were O
colocalized O
to O
the O
c O
- O
d O
band O
of O
mouse O
chromosome O
9 O
, O
the O
proximal O
end O
of O
q24 O
. O
	
1 O
of O
rat O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
syrian O
hamster O
chromosome O
12 O
. O
	
the O
regions O
in O
the O
mouse O
and O
rat O
were O
homologous O
to O
human O
chromosome O
11q O
. O
	
fine O
genetic O
linkage O
mapping O
of O
the O
mouse O
at B-Disease
region O
was O
performed O
using O
the O
interspecific O
backcross O
mice O
. O
	
atm O
, O
acat1 O
, O
and O
npat O
, O
which O
is O
a O
new O
gene O
isolated O
from O
the O
at O
region O
, O
and O
12 O
flanking O
microsatellite O
dna O
markers O
were O
examined O
. O
	
no O
recombinations O
were O
found O
among O
the O
atm O
, O
npat O
, O
acat1 O
, O
and O
d9mit6 O
loci O
, O
and O
these O
loci O
were O
mapped O
2 O
. O
	
0 O
cm O
distal O
to O
d9mit99 O
and O
1 O
. O
	
3 O
cm O
proximal O
to O
d9mit102 O
. O
	
comparison O
of O
the O
linkage O
map O
of O
mouse O
chromosome O
9 O
( O
mmu9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
hsa11 O
) O
indicates O
that O
there O
is O
a O
chromosomal O
rearrangement O
due O
to O
an O
inversion O
between O
ets1 O
and O
atm O
- O
npat O
- O
acat1 O
and O
that O
the O
inversion O
of O
mmu9 O
originated O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
gria4 O
and O
atm O
- O
npat O
- O
acat1 O
on O
hsa11 O
. O
	
this O
type O
of O
inversion O
appeared O
to O
be O
conserved O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
and O
syrian O
hamster O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
rck O
gene O
an O
animal O
model O
for O
norrie B-Disease
disease I-Disease
( O
nd B-Disease
) O
: O
gene O
targeting O
of O
the O
mouse O
nd B-Disease
gene O
. O
	
in O
order O
to O
elucidate O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
norrie B-Disease
disease I-Disease
( O
nd B-Disease
) O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
nd B-Disease
mutant O
mice O
. O
	
the O
murine O
homologue O
of O
the O
nd B-Disease
gene O
was O
cloned O
and O
shown O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
% O
of O
the O
amino O
acid O
sequence O
with O
its O
human O
counterpart O
. O
	
rna O
in O
situ O
hybridization O
revealed O
expression O
in O
retina O
, O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
week O
old O
mice O
. O
	
hemizygous O
mice O
carrying O
a O
replacement O
mutation O
in O
exon O
2 O
of O
the O
nd B-Disease
gene O
developed O
retrolental O
structures O
in O
the O
vitreous O
body O
and O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
. O
	
the O
outer O
plexiform O
layer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O
outer O
nuclear O
layer O
. O
	
at O
the O
same O
regions O
, O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
longer O
present O
. O
	
these O
ocular O
findings O
are O
consistent O
with O
observations O
in O
nd B-Disease
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
pathogenic O
events O
in O
this O
severe O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
neurological I-Disease
disorder I-Disease
. O
	
. O
	
the O
hybrid O
pax3 O
- O
fkhr O
fusion O
protein O
of O
alveolar B-Disease
rhabdomyosarcoma I-Disease
transforms O
fibroblasts O
in O
culture O
. O
	
pediatric B-Disease
alveolar I-Disease
rhabdomyosarcoma I-Disease
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
pax3 O
and O
fkhr O
genes O
. O
	
pax3 O
codes O
for O
a O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
fkhr O
codes O
for O
a O
forkhead O
- O
winged O
helix O
protein O
, O
also O
a O
likely O
transcription O
factor O
. O
	
the O
pax3 O
- O
fkhr O
fusion O
product O
retains O
the O
dna O
binding O
domains O
of O
the O
pax3 O
protein O
and O
the O
putative O
activator O
domain O
of O
the O
fkhr O
protein O
. O
	
the O
pax3 O
- O
fkhr O
protein O
has O
been O
shown O
to O
function O
as O
a O
transcriptional O
activator O
. O
	
using O
the O
rcas O
retroviral O
vector O
, O
we O
have O
introduced O
the O
pax3 O
- O
fkhr O
gene O
into O
chicken O
embryo O
fibroblasts O
. O
	
expression O
of O
the O
pax3 O
- O
fkhr O
protein O
in O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
tightly O
packed O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchorage O
- O
independent O
growth O
. O
	
this O
cellular O
transformation O
in O
vitro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
pax3 O
- O
fkhr O
- O
induced O
oncogenesis O
. O
	
. O
	
somatic O
- O
cell O
selection O
is O
a O
major O
determinant O
of O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe O
enzyme B-Disease
deficiency I-Disease
. O
	
x O
- O
chromosome O
inactivation O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
somatic O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O
cell O
selection O
. O
	
in O
most O
people O
with O
red O
- O
blood O
- O
cell O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
. O
	
however O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B-Disease
nonspherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
, O
the O
underlying O
mutations O
( O
designated O
class O
i O
) O
cause O
more O
- O
severe O
g6pd B-Disease
deficiency I-Disease
, O
and O
this O
might O
provide O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O
during O
development O
. O
	
in O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
heterozygotes O
for O
class O
i O
g6pd O
mutations O
two O
with O
g6pd O
portici O
( O
1178g O
- O
- O
> O
a O
) O
and O
two O
with O
g6pd O
bari O
( O
1187c O
- O
- O
> O
t O
) O
. O
	
we O
found O
that O
in O
fractionated O
blood O
cell O
types O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
) O
there O
was O
a O
significant O
excess O
of O
g6pd O
- O
normal O
cells O
. O
	
the O
significant O
concordance O
that O
we O
have O
observed O
in O
the O
degree O
of O
imbalance O
in O
the O
different O
blood O
- O
cell O
lineages O
indicates O
that O
a O
selective O
mechanism O
is O
likely O
to O
operate O
at O
the O
level O
of O
pluripotent O
blood O
stem O
cells O
. O
	
thus O
, O
it O
appears O
that O
severe O
g6pd B-Disease
deficiency I-Disease
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O
. O
	
. O
	
analysis O
of O
meiotic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B-Disease
dystrophy I-Disease
locus O
. O
	
meiotic O
drive O
at O
the O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
locus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
dm B-Disease
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
state O
. O
	
in O
order O
to O
test O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
single O
sperm O
from O
three O
individuals O
heterozygous O
at O
the O
dm B-Disease
locus O
, O
each O
with O
one O
allele O
larger O
and O
one O
allele O
smaller O
than O
19 O
ctg O
repeats O
. O
	
to O
guard O
against O
the O
possible O
problem O
of O
differential O
pcr O
amplification O
rates O
based O
on O
the O
lengths O
of O
the O
alleles O
, O
the O
sperm O
were O
also O
typed O
at O
another O
closely O
linked O
marker O
whose O
allele O
size O
was O
unrelated O
to O
the O
allele O
size O
at O
the O
dm B-Disease
locus O
. O
	
using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
meiotic O
segregation O
distortion O
. O
	
the O
upper O
limit O
of O
the O
two O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
segregation O
probability O
for O
the O
three O
donors O
is O
at O
or O
below O
. O
	
515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
significant O
difference O
from O
. O
	
5 O
is O
detected O
in O
any O
of O
the O
models O
. O
	
this O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
myotonic B-Disease
dystrophy I-Disease
locus O
must O
result O
from O
events O
following O
sperm O
ejaculation O
. O
	
lpp O
, O
the O
preferred O
fusion O
partner O
gene O
of O
hmgic O
in O
lipomas B-Disease
, O
is O
a O
novel O
member O
of O
the O
lim O
protein O
gene O
family O
. O
	
a O
major O
cytogenetic O
subgroup O
of O
lipomas B-Disease
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
chromosome O
segment O
12q13 O
- O
q15 O
. O
	
multiple O
chromosomes O
have O
been O
found O
as O
the O
translocation O
partners O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
involved O
. O
	
in O
previous O
studies O
, O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
hmg O
) O
protein O
gene O
hmgic O
at O
12q15 O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O
translocations O
. O
	
here O
, O
we O
report O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
gene O
, O
which O
we O
have O
designated O
lpp O
( O
lipoma B-Disease
preferred O
partner O
gene O
) O
. O
	
using O
3 O
- O
race O
analysis O
of O
hmgic O
fusion O
transcripts O
in O
lipoma B-Disease
cell O
line O
li O
- O
501 O
/ O
sv40 O
, O
ectopic O
genetic O
sequences O
were O
obtained O
, O
which O
by O
cash O
( O
chromosome O
assignment O
using O
somatic O
cell O
hybrids O
) O
and O
fish O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
were O
found O
to O
originate O
from O
chromosome O
segment O
3q27 O
- O
q28 O
. O
	
in O
northern O
blot O
analysis O
, O
an O
mrna O
of O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
. O
	
upon O
partial O
cdna O
cloning O
, O
features O
of O
the O
genetic O
organization O
of O
lpp O
were O
established O
. O
	
the O
gene O
was O
found O
to O
span O
a O
genomic O
region O
of O
over O
400 O
kb O
. O
	
nucleotide O
sequence O
analysis O
of O
a O
composite O
cdna O
of O
lpp O
revealed O
an O
open O
reading O
frame O
of O
1836 O
nucleotides O
encoding O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
three O
lim O
domains O
in O
its O
carboxy O
- O
terminal O
region O
. O
	
the O
lpp O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
the O
lim O
protein O
gene O
family O
. O
	
using O
reverse O
transcriptase O
combined O
with O
polymerase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lipoma B-Disease
cell O
lines O
and O
primary B-Disease
lipomas I-Disease
, O
it O
appeared O
that O
lpp O
is O
frequently O
rearranged O
also O
in O
cases O
without O
a O
cytogenetically O
detectable O
involvement O
of O
3q27 O
- O
q28 O
. O
	
two O
alternative O
hmgic O
/ O
lpp O
hybrid O
transcripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
lim O
domains O
in O
the O
predicted O
hmgi O
- O
c O
/ O
lpp O
fusion O
proteins O
. O
	
. O
	
absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
cag O
repeat O
in O
transgenic O
mice O
expressing O
the O
human O
huntington B-Disease
disease I-Disease
transcript O
. O
	
the O
mutation O
underlying O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
is O
cag O
expansion O
in O
the O
first O
exon O
of O
the O
hd B-Disease
gene O
. O
	
in O
order O
to O
investigate O
the O
role O
of O
cag O
expansion O
in O
the O
pathogenesis O
of O
hd B-Disease
, O
we O
have O
produced O
transgenic O
mice O
containing O
the O
full O
length O
human O
hd B-Disease
cdna O
with O
44 O
cag O
repeats O
. O
	
by O
1 O
year O
, O
these O
mice O
have O
no O
behavioral B-Disease
abnormalities I-Disease
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O
	
despite O
high O
levels O
of O
mrna O
expression O
, O
there O
was O
no O
evidence O
of O
the O
hd B-Disease
gene O
product O
in O
any O
of O
these O
transgenic O
mice O
. O
	
in O
vitro O
transfection O
studies O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
5 O
utr O
in O
the O
cdna O
construct O
and O
the O
presence O
of O
a O
frameshift O
mutation O
at O
nucleotide O
2349 O
prevented O
expression O
of O
the O
hd B-Disease
cdna O
. O
	
these O
findings O
suggest O
that O
the O
pathogenesis O
of O
hd B-Disease
is O
not O
mediated O
through O
dna O
- O
protein O
interaction O
and O
that O
presence O
of O
the O
rna O
transcript O
with O
an O
expanded O
cag O
repeat O
is O
insufficient O
to O
cause O
the O
disease O
. O
	
rather O
, O
translation O
of O
the O
cag O
is O
crucial O
for O
the O
pathogenesis O
of O
hd B-Disease
. O
	
in O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
cag O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
97 O
meioses O
. O
	
this O
suggests O
that O
genomic O
sequences O
may O
play O
a O
critical O
role O
in O
influencing O
repeat O
instability O
. O
	
. O
	
fish O
studies O
in O
a O
patient O
with O
sporadic B-Disease
aniridia I-Disease
and O
t O
( O
7 O
; O
11 O
) O
( O
q31 O
. O
	
2 O
; O
p13 O
) O
. O
	
a O
2 O
year O
old O
female O
presenting O
with O
bilateral B-Disease
sporadic I-Disease
aniridia I-Disease
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
within O
band O
p13 O
. O
	
fluorescence O
in O
situ O
hybridisation O
( O
fish O
) O
studies O
with O
distal O
11p13 O
specific O
cosmids O
showed O
that O
the O
chromosome O
11 O
breakpoint O
lay O
between O
the O
aniridia B-Disease
( O
pax6 O
) O
locus O
and O
a O
region O
approximately O
100 O
kb O
distal O
to O
pax6 O
defined O
by O
the O
cosmid O
fo2121 O
. O
	
although O
this O
patient O
did O
not O
have O
a O
detectable O
deletion O
within O
pax6 O
, O
her O
aniridia B-Disease
may O
have O
resulted O
from O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
pax6 O
. O
	
this O
case O
may O
therefore O
be O
another O
example O
of O
aniridia B-Disease
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two O
familial B-Disease
aniridia I-Disease
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome B-Disease
abnormalities I-Disease
with O
11p13 O
breakpoints O
. O
	
. O
	
muscle O
expression O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
in O
different O
variants O
. O
	
muscle O
expression O
of O
g6pd B-Disease
deficiency I-Disease
has O
been O
investigated O
in O
mediterranean O
, O
seattle O
- O
like O
and O
a O
- O
variants O
. O
	
g6pd O
activity O
was O
detected O
in O
samples O
obtained O
from O
biopsies O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
female O
. O
	
the O
type O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
of O
dna O
, O
extracted O
from O
blood O
samples O
. O
	
all O
variants O
showed O
the O
enzyme O
defect O
in O
muscle O
. O
	
a O
statistically O
significant O
relationship O
was O
found O
in O
the O
activity O
of O
g6pd O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
	
968 O
; O
p O
= O
0 O
. O
	
00008 O
) O
. O
	
the O
equation O
for O
the O
best O
fit O
line O
was O
y O
= O
0 O
. O
	
390x O
+ O
0 O
. O
	
198 O
198 O
. O
	
the O
results O
suggest O
that O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
g6pd O
activity O
of O
erythrocytes O
gene O
therapy O
for O
phenylketonuria B-Disease
. O
	
classical O
phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
hepatic I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O
	
limitations O
of O
the O
current O
dietary O
treatment O
for O
pku B-Disease
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
somatic O
gene O
transfer O
. O
	
three O
different O
vector O
systems O
have O
been O
examined O
. O
	
vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
dna O
/ O
protein O
complex O
can O
efficiently O
transduce O
the O
pah O
cdna O
into O
pah B-Disease
- I-Disease
deficient I-Disease
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
by O
their O
low O
transduction O
efficiency O
in O
vivo O
. O
	
in O
contrast O
, O
a O
vector O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
hepatic O
pah O
activity O
into O
pah B-Disease
- I-Disease
deficient I-Disease
mice O
, O
which O
completely O
normalizes O
serum O
phenylalanine O
levels O
. O
	
this O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
directed O
against O
the O
recombinant O
adenoviral O
vector O
. O
	
however O
, O
these O
findings O
suggest O
that O
pku B-Disease
can O
be O
completely O
corrected O
by O
somatic O
gene O
therapy O
, O
and O
provide O
some O
direction O
for O
the O
future O
development O
of O
adenoviral O
vectors O
. O
	
. O
	
exon O
- O
intron O
structure O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
chrna4 O
) O
. O
	
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
chrna4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign B-Disease
familial I-Disease
neonatal I-Disease
convulsions I-Disease
, O
autosomal B-Disease
dominant I-Disease
nocturnal I-Disease
frontal I-Disease
lobe I-Disease
epilepsy I-Disease
, O
and O
low O
- O
voltage O
eeg O
. O
	
recently O
, O
a O
missense O
mutation O
in O
transmembrane O
domain O
2 O
of O
chrna4 O
was O
found O
to O
be O
associated O
with O
autosomal B-Disease
dominant I-Disease
nocturnal I-Disease
frontal I-Disease
lobe I-Disease
epilepsy I-Disease
in O
one O
extended O
pedigree O
. O
	
we O
have O
determined O
the O
genomic O
organization O
of O
chrna4 O
, O
which O
consists O
of O
six O
exons O
distributed O
over O
approximately O
17 O
kb O
of O
genomic O
dna O
. O
	
the O
nucleotide O
sequence O
obtained O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
a O
set O
of O
primer O
pairs O
for O
pcr O
amplification O
of O
the O
complete O
coding O
region O
. O
	
the O
sequence O
analysis O
provides O
the O
basis O
for O
a O
comprehensive O
mutation O
screening O
of O
chrna4 O
in O
the O
above O
- O
mentioned O
phenotypes O
and O
possibly O
in O
other O
types O
of O
idiopathic B-Disease
epilepsies I-Disease
. O
	
. O
	
ashkenazi O
jewish O
population O
frequencies O
for O
common O
mutations O
in O
brca1 O
and O
brca2 O
. O
	
brca1 O
and O
brca2 O
are O
the O
two O
major O
identified O
causes O
of O
inherited B-Disease
breast I-Disease
cancer I-Disease
, O
with O
mutations O
in O
either O
gene O
conferring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
in O
carrier O
females O
. O
	
mutations O
in O
brca1 O
account O
for O
approximately O
45 O
% O
of O
familial B-Disease
breast I-Disease
cancer I-Disease
and O
90 O
% O
of O
inherited B-Disease
breast I-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
, O
whereas O
mutations O
in O
brca2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B-Disease
breast I-Disease
cancer I-Disease
cases O
. O
	
over O
85 O
distinct O
brca1 O
mutations O
and O
a O
growing O
list O
of O
brca2 O
mutations O
have O
been O
identified O
, O
with O
the O
majority O
resulting O
in O
protein O
truncation O
. O
	
a O
specific O
brca1 O
mutation O
, O
185delag O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
. O
	
9 O
% O
in O
the O
ashkenazi O
jewish O
population O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
jewish O
patients O
with O
a O
different O
haplotype O
. O
	
the O
6174delt O
mutation O
in O
brca2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
ashkenazi O
jewish O
women O
diagnosed O
with O
breast B-Disease
cancer I-Disease
by O
age O
50 O
( O
ref O
. O
	
8 O
) O
, O
as O
well O
as O
in O
three O
ashkenazi O
male B-Disease
breast I-Disease
cancer I-Disease
patients O
. O
	
we O
have O
conducted O
a O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
brca1 O
and O
brca2 O
mutations O
in O
ashkenazi O
jewish O
individuals O
who O
were O
unselected O
for O
breast B-Disease
cancer I-Disease
. O
	
brca1 O
mutation O
screening O
on O
approximately O
3 O
, O
000 O
ashkenazi O
jewish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
. O
	
09 O
% O
for O
the O
185delag O
mutation O
and O
0 O
. O
	
13 O
% O
for O
the O
5382insc O
mutation O
. O
	
brca2 O
analysis O
on O
3 O
, O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
. O
	
52 O
% O
for O
the O
6174delt O
mutation O
. O
	
this O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
brca1 O
185delag O
mutation O
and O
the O
brca2 O
6174delt O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B-Disease
breast I-Disease
cancer I-Disease
among O
the O
ashkenazim O
, O
and O
suggests O
a O
relatively O
lower O
penetrance O
for O
the O
6174delt O
mutation O
in O
brca2 O
dual O
roles O
of O
atm O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O
. O
	
the O
gene O
mutated O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
at B-Disease
) O
patients O
, O
denoted O
atm O
, O
encodes O
a O
putative O
protein O
or O
lipid O
kinase O
. O
	
to O
elucidate O
the O
functions O
of O
atm O
, O
we O
disrupted O
the O
mouse O
atm O
gene O
through O
homologous O
recombination O
in O
mice O
. O
	
consistent O
with O
cellular O
defects O
of O
at B-Disease
patients O
, O
the O
atm O
- O
/ O
- O
cells O
are O
hypersensitive O
to O
gamma O
- O
irradiation O
and O
defective O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
correlating O
with O
a O
defective O
up O
- O
regulation O
of O
p53 O
. O
	
in O
addition O
, O
atm O
- O
/ O
- O
mouse O
thymocytes O
are O
more O
resistant O
to O
apoptosis O
induced O
by O
gamma O
- O
irradiation O
than O
normal O
thymocytes O
. O
	
atm O
- O
/ O
- O
fibroblasts O
are O
inefficient O
in O
g1 O
to O
s O
- O
phase O
progression O
following O
serum O
stimulation O
and O
senesce O
after O
only O
a O
few O
passages O
in O
culture O
. O
	
they O
have O
an O
increased O
constitutive O
level O
of O
p21cp1 O
/ O
waf1 O
. O
	
the O
atm O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
and O
for O
normal O
cell O
- O
cycle O
progression O
. O
	
atm O
+ O
/ O
- O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
to O
irradiation O
but O
no O
growth O
defect O
, O
suggesting O
that O
the O
increased O
cancer B-Disease
risk O
of O
at B-Disease
heterozygotes O
could O
be O
attributable O
to O
poor O
checkpoint O
function O
. O
	
. O
	
targeted O
disruption O
of O
atm O
leads O
to O
growth B-Disease
retardation I-Disease
, O
chromosomal B-Disease
fragmentation I-Disease
during I-Disease
meiosis I-Disease
, O
immune B-Disease
defects I-Disease
, O
and O
thymic B-Disease
lymphoma I-Disease
. O
	
atm O
, O
the O
gene O
mutated O
in O
the O
inherited B-Disease
human I-Disease
disease I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
dna O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O
	
to O
help O
clarify O
the O
physiological O
roles O
of O
the O
atm O
protein O
, O
we O
disrupted O
the O
atm O
gene O
in O
mice O
through O
homologous O
recombination O
. O
	
initial O
evaluation O
of O
the O
atm O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
atm O
gene O
recreates O
much O
of O
the O
phenotype O
of O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
. O
	
the O
homozygous O
mutant O
( O
atm O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth O
- O
retarded O
, O
and O
infertile O
. O
	
the O
infertility B-Disease
of O
atm O
- O
/ O
- O
mice O
results O
from O
meiotic O
failure O
. O
	
meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
i O
as O
a O
result O
of O
abnormal O
chromosomal O
synapsis O
and O
subsequent O
chromosome O
fragmentation O
. O
	
immune B-Disease
defects I-Disease
also O
are O
evident O
in O
atm O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
b220 O
+ O
cd43 O
- O
pre O
- O
b O
cells O
, O
thymocytes O
, O
and O
peripheral O
t O
cells O
, O
as O
well O
as O
functional O
impairment O
of O
t O
- O
cell O
- O
dependent O
immune O
responses O
. O
	
the O
cerebella O
of O
atm O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
to O
4 O
months O
and O
the O
mice O
have O
no O
gross O
behavioral B-Disease
abnormalities I-Disease
. O
	
the O
majority O
of O
mutant O
mice O
rapidly O
develop O
thymic B-Disease
lymphomas I-Disease
and O
die O
before O
4 O
months O
of O
age O
. O
	
these O
findings O
indicate O
that O
the O
atm O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B-Disease
suppression O
. O
	
. O
	
cloning O
and O
characterization O
of O
human O
very O
- O
long O
- O
chain O
acyl O
- O
coa O
dehydrogenase O
cdna O
, O
chromosomal O
assignment O
of O
the O
gene O
and O
identification O
in O
four O
patients O
of O
nine O
different O
mutations O
within O
the O
vlcad O
gene O
. O
	
very O
- O
long O
- O
chain O
acyl O
- O
coa O
dehydrogenase O
( O
vlcad O
) O
is O
one O
of O
four O
straight O
- O
chain O
acyl O
- O
coa O
dehydrogenase O
( O
acd O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
catalyzing O
the O
initial O
step O
in O
fatty O
acid O
beta O
- O
oxidation O
. O
	
we O
have O
used O
the O
very O
fast O
, O
rapid O
amplification O
of O
cdna O
ends O
( O
race O
) O
based O
strategy O
to O
obtain O
the O
sequence O
of O
cdnas O
encoding O
human O
vlcad O
from O
placenta O
and O
fibroblasts O
. O
	
alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
vlcad O
with O
those O
of O
the O
other O
human O
acd O
enzymes O
revealed O
extensive O
sequence O
homology O
. O
	
moreover O
, O
human O
vlcad O
and O
human O
acyl O
- O
coa O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
these O
genes O
are O
evolutionarily O
related O
. O
	
southern O
blot O
analysis O
of O
genomic O
dna O
from O
hybrid O
cell O
lines O
was O
used O
to O
localize O
the O
vlcad O
gene O
to O
human O
chromosome O
17p11 O
. O
	
2 O
- O
p11 O
. O
	
13105 O
. O
	
using O
northern O
and O
western O
blot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
vlcad O
mrna O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
vlcad O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
. O
	
this O
agrees O
well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
vlcad B-Disease
deficiency I-Disease
. O
	
northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
pcr O
amplified O
vlcad O
cdna O
from O
four O
unrelated O
patients O
with O
vlcad B-Disease
deficiency I-Disease
showed O
that O
vlcad O
mrna O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
vlcad O
alleles O
. O
	
western O
blot O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
vlcad O
protein O
. O
	
molecular O
bases O
of O
combined B-Disease
subtotal I-Disease
deficiencies I-Disease
of I-Disease
c6 I-Disease
and I-Disease
c7 I-Disease
: O
their O
effects O
in O
combination O
with O
other O
c6 B-Disease
and I-Disease
c7 I-Disease
deficiencies I-Disease
. O
	
combined B-Disease
subtotal I-Disease
deficiency I-Disease
of I-Disease
c6 I-Disease
and I-Disease
c7 I-Disease
, O
in O
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
, O
has O
been O
observed O
in O
homozygous O
form O
in O
two O
families O
. O
	
a O
defect O
at O
the O
5 O
splice O
donor O
site O
of O
intron O
15 O
of O
the O
c6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
c6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
. O
	
the O
c7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
and O
altered O
isoelectric O
point O
. O
	
an O
arg O
> O
ser O
codon O
substitution O
in O
exon O
11 O
is O
the O
only O
molecular O
alteration O
within O
the O
mature O
c7 O
protein O
. O
	
these O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
dna O
markers O
in O
the O
c6 O
/ O
c7 O
region O
, O
forming O
a O
distinct O
haplotype O
. O
	
the O
haplotype O
has O
been O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
either O
to O
c6 B-Disease
or I-Disease
c7 I-Disease
deficiency I-Disease
, O
but O
with O
different O
consequences O
. O
	
where O
it O
is O
combined O
with O
a O
c6 B-Disease
- I-Disease
deficient I-Disease
gene O
, O
the O
serum O
c7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
c6 O
generating O
c56 O
to O
consume O
the O
c7 O
. O
	
in O
contrast O
, O
where O
the O
c7 O
genes O
are O
both O
defective O
( O
but O
still O
partially O
functional O
) O
, O
there O
may O
be O
a O
profound O
deficit O
of O
circulating O
c7 O
because O
there O
is O
ample O
c6 O
to O
produce O
c56 O
and O
consume O
the O
already O
small O
amount O
of O
c7 O
. O
	
each O
molecular O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
	
. O
	
genetic O
bases O
of O
human O
complement B-Disease
c7 I-Disease
deficiency I-Disease
. O
	
complement B-Disease
c7 I-Disease
deficiency I-Disease
( O
c7d B-Disease
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B-Disease
infections I-Disease
, O
especially O
meningitis B-Disease
caused O
by O
neisseria B-Disease
meningitidis I-Disease
. O
	
we O
report O
in O
this O
work O
the O
molecular O
bases O
of O
c7d B-Disease
in O
two O
unrelated O
japanese O
males O
. O
	
we O
used O
exon O
- O
specific O
pcr O
/ O
single O
- O
strand O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
mutations O
. O
	
subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
in O
exon O
15 O
of O
case O
2 O
. O
	
the O
mutation O
of O
case O
1 O
was O
a O
homozygous O
t O
to O
a O
transversion O
at O
nucleotide O
2250 O
, O
the O
third O
nucleotide O
of O
the O
codon O
tgt O
for O
cys728 O
, O
leading O
to O
a O
stop O
codon O
tga O
( O
c728x O
) O
. O
	
in O
case O
2 O
, O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137deltg O
/ O
2138delgt O
/ O
2139deltg O
) O
caused O
a O
frameshift O
, O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
. O
	
family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
of O
the O
defect O
. O
	
moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
for O
c7d B-Disease
in O
case O
1 O
. O
	
our O
results O
indicate O
that O
the O
pathogenesis O
of O
c7d B-Disease
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B-Disease
of I-Disease
complement I-Disease
components I-Disease
. O
	
. O
	
hprt B-Disease
- I-Disease
aprt I-Disease
- I-Disease
deficient I-Disease
mice O
are O
not O
a O
model O
for O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O
	
complete B-Disease
hypoxanthine I-Disease
- I-Disease
guanine I-Disease
phosphoribosyl I-Disease
- I-Disease
transferase I-Disease
( I-Disease
hprt I-Disease
) I-Disease
deficiency I-Disease
in O
humans O
results O
in O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
. O
	
hprt B-Disease
- I-Disease
deficient I-Disease
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O
	
administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
aprt O
) O
in O
hprt B-Disease
- I-Disease
deficient I-Disease
mice O
has O
produced O
the O
suggestion O
that O
deficiency B-Disease
of I-Disease
aprt I-Disease
in O
combination O
with O
hprt B-Disease
- I-Disease
deficiency I-Disease
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
c O
. O
	
l O
. O
	
wu O
and O
d O
. O
	
w O
. O
	
melton O
( O
1993 O
) O
nature O
genet O
. O
	
3 O
, O
235 O
- O
240 O
] O
. O
	
to O
test O
this O
proposition O
, O
we O
bred O
hprt B-Disease
- I-Disease
aprt I-Disease
- I-Disease
deficient I-Disease
mice O
. O
	
although O
the O
doubly O
- O
deficient O
mice O
excrete O
adenine O
and O
its O
highly O
insoluble O
derivative O
, O
2 O
, O
8 O
- O
dihydroxyadenine O
, O
which O
are O
also O
associated O
with O
human O
aprt B-Disease
deficiency I-Disease
, O
additional O
abnormalities O
or O
any O
self O
- O
injurious O
behavior O
were O
not O
detected O
. O
	
thus O
, O
aprt B-Disease
- I-Disease
hprt I-Disease
- I-Disease
deficient I-Disease
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral B-Disease
abnormalities I-Disease
associated O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
as O
previously O
suggested O
somatic O
alterations O
of O
the O
dpc4 O
gene O
in O
human O
colorectal B-Disease
cancers I-Disease
in O
vivo O
. O
	
background O
& O
aims O
the O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B-Disease
cancers I-Disease
, O
and O
such O
frequent O
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
. O
	
the O
dpc4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
gene O
from O
examination O
of O
pancreatic B-Disease
cancers I-Disease
. O
	
the O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B-Disease
cancers I-Disease
. O
	
methods O
mutation O
analyses O
of O
the O
dpc4 O
gene O
were O
performed O
on O
complementary O
dna O
samples O
from O
31 O
primary O
colorectal B-Disease
cancer I-Disease
specimens O
using O
a O
combination O
of O
polymerase O
chain O
reaction O
, O
single O
- O
strand O
conformation O
polymorphism O
, O
and O
dna O
sequencing O
. O
	
results O
four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
dpc4 O
gene O
were O
detected O
in O
the O
31 O
cancers B-Disease
( O
16 O
% O
; O
5 O
of O
31 O
) O
. O
	
conclusions O
the O
dpc4 O
gene O
may O
play O
a O
role O
as O
a O
tumor O
- O
suppressor O
gene O
in O
a O
fraction O
of O
colorectal B-Disease
cancers I-Disease
; O
however O
, O
while O
allelic O
loss O
at O
18q21 O
is O
very O
often O
seen O
in O
colorectal B-Disease
cancers I-Disease
, O
only O
a O
minority O
show O
dpc4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
in O
this O
chromosome O
region O
. O
	
. O
	
pleiotropic O
defects O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
protein O
- O
deficient O
mice O
. O
	
we O
have O
generated O
a O
mouse O
model O
for O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
do O
not O
express O
the O
atm O
protein O
. O
	
atm O
- O
deficient O
mice O
are O
retarded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
defects O
in O
t O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B-Disease
. O
	
atm O
- O
deficient O
fibroblasts O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
breaks O
. O
	
atm O
- O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
significantly O
more O
than O
controls O
. O
	
atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
patients O
and O
in O
cells O
derived O
from O
them O
. O
	
furthermore O
, O
we O
demonstrate O
that O
the O
atm O
protein O
exists O
as O
two O
discrete O
molecular O
species O
, O
and O
that O
loss O
of O
one O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
development O
of O
the O
disease O
. O
	
. O
	
the O
dcc O
protein O
and O
prognosis O
in O
colorectal B-Disease
cancer I-Disease
. O
	
background O
allelic O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B-Disease
ii I-Disease
colorectal I-Disease
cancer I-Disease
. O
	
although O
the O
specific O
gene O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
dcc O
( O
deleted O
in O
colorectal B-Disease
cancer I-Disease
) O
gene O
is O
a O
candidate O
. O
	
we O
investigated O
whether O
the O
expression O
of O
the O
dcc O
protein O
in O
tumor B-Disease
cells O
is O
a O
prognostic O
marker O
in O
colorectal B-Disease
carcinoma I-Disease
. O
	
methods O
the O
expression O
of O
dcc O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
samples O
from O
patients O
with O
curatively O
resected O
stage B-Disease
ii I-Disease
and I-Disease
iii I-Disease
colorectal I-Disease
carcinomas I-Disease
. O
	
the O
cox O
proportional O
- O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, O
tumor B-Disease
site O
, O
degree O
of O
tumor B-Disease
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
. O
	
results O
the O
expression O
of O
dcc O
was O
a O
strong O
positive O
predictive O
factor O
for O
survival O
in O
both O
stage B-Disease
ii I-Disease
and I-Disease
stage I-Disease
iii I-Disease
colorectal I-Disease
carcinomas I-Disease
. O
	
in O
patients O
with O
stage O
ii O
disease O
whose O
tumors B-Disease
expressed O
dcc O
, O
the O
five O
- O
year O
survival O
rate O
was O
94 O
. O
	
3 O
percent O
, O
whereas O
in O
patients O
with O
dcc B-Disease
- I-Disease
negative I-Disease
tumors I-Disease
, O
the O
survival O
rate O
was O
61 O
. O
	
6 O
percent O
( O
p O
< O
0 O
. O
	
001 O
) O
. O
	
in O
patients O
with O
stage B-Disease
iii I-Disease
disease I-Disease
, O
the O
respective O
survival O
rates O
were O
59 O
. O
	
3 O
percent O
and O
33 O
. O
	
2 O
percent O
( O
p O
= O
0 O
. O
	
03 O
) O
. O
	
conclusions O
dcc O
is O
a O
prognostic O
marker O
in O
patients O
with O
stage B-Disease
ii I-Disease
or I-Disease
stage I-Disease
iii I-Disease
colorectal I-Disease
cancer I-Disease
. O
	
in O
stage B-Disease
ii I-Disease
colorectal I-Disease
carcinomas I-Disease
, O
the O
absence O
of O
dcc O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B-Disease
iii I-Disease
cancers I-Disease
. O
	
these O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
group O
of O
patients O
association O
of O
anxiety B-Disease
- I-Disease
related I-Disease
traits I-Disease
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
. O
	
transporter O
- O
facilitated O
uptake O
of O
serotonin O
( O
5 O
- O
hydroxytryptamine O
or O
5 O
- O
ht O
) O
has O
been O
implicated O
in O
anxiety B-Disease
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
uptake O
- O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O
	
human O
5 O
- O
ht O
transporter O
( O
5 O
- O
htt O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
in O
its O
upstream O
regulatory O
region O
. O
	
the O
short O
variant O
of O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
htt O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
htt O
expression O
and O
5 O
- O
ht O
uptake O
in O
lymphoblasts O
. O
	
association O
studies O
in O
two O
independent O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
htt O
polymorphism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B-Disease
- I-Disease
related I-Disease
personality I-Disease
traits I-Disease
in O
individuals O
as O
well O
as O
sibships O
. O
	
. O
	
phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B-Disease
type I-Disease
2 I-Disease
and O
diastrophic B-Disease
dysplasia I-Disease
. O
	
mutations O
in O
the O
diastrophic B-Disease
dysplasia I-Disease
sulfate O
transporter O
gene O
dtdst O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B-Disease
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B-Disease
dysplasia I-Disease
( O
dtd B-Disease
) O
, O
atelosteogenesis B-Disease
type I-Disease
2 I-Disease
( O
ao2 B-Disease
) O
, O
and O
achondrogenesis B-Disease
type I-Disease
1b I-Disease
( O
acg1b B-Disease
) O
. O
	
to O
learn O
more O
about O
the O
molecular O
basis O
of O
dtdst B-Disease
chondrodysplasias I-Disease
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
ao B-Disease
- I-Disease
2 I-Disease
, O
one O
with O
dtd B-Disease
, O
and O
one O
with O
an O
intermediate O
phenotype O
( O
ao2 B-Disease
/ O
dtd B-Disease
) O
. O
	
reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
in O
all O
three O
. O
	
each O
of O
the O
three O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
transition O
predicting O
a O
r279w O
substitution O
in O
the O
third O
extracellular O
loop O
of O
dtdst O
. O
	
in O
two O
patients O
( O
dtd B-Disease
and O
ao2 B-Disease
/ O
dtd B-Disease
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
and O
single O
- O
strand O
conformation O
polymorphism O
analysis O
of O
fibroblast O
cdna O
showed O
reduced O
mrna O
levels O
of O
the O
wild O
- O
type O
dtdst O
allele O
these O
two O
patients O
may O
be O
compound O
heterozygotes O
for O
the O
finnish O
mutation O
( O
as O
yet O
uncharacterized O
at O
the O
dna O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
dtdst O
. O
	
the O
third O
patient O
( O
with O
ao2 B-Disease
) O
had O
the O
r279w O
mutation O
compounded O
with O
a O
novel O
mutation O
, O
the O
deletion O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
predicting O
a O
frameshift O
with O
premature O
termination O
. O
	
also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cdna O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
stop O
codons O
reduce O
mrna O
levels O
. O
	
the O
presence O
of O
the O
dtdst O
r279w O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
ao2 B-Disease
or O
dtd B-Disease
emphasizes O
the O
overlap O
between O
these O
conditions O
. O
	
this O
mutation O
has O
not O
been O
found O
so O
far O
in O
8 O
analyzed O
acg1b B-Disease
patients O
, O
suggesting O
that O
it O
allows O
some O
residual O
activity O
of O
the O
sulfate O
transporter O
. O
	
. O
	
identification O
of O
wasp O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
. O
	
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
, O
an O
x B-Disease
- I-Disease
linked I-Disease
immunodeficiency I-Disease
disease I-Disease
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
was B-Disease
protein O
( O
wasp O
) O
, O
is O
known O
to O
be O
associated O
with O
extensive O
clinical O
heterogeneity O
. O
	
cumulative O
mutation O
data O
have O
revealed O
that O
wasp O
genotypes O
are O
also O
highly O
variable O
among O
was B-Disease
patients O
, O
but O
the O
relationship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
remains O
unclear O
. O
	
to O
address O
this O
issue O
we O
characterized O
wasp O
mutations O
in O
24 O
unrelated O
was B-Disease
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
was B-Disease
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
wasp O
mutations O
with O
disease O
severity O
. O
	
by O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
clustering O
of O
wasp O
mutations O
within O
the O
four O
most O
n O
- O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
for O
wasp O
mutation O
. O
	
these O
characteristics O
were O
observed O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
. O
	
similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
predominance O
of O
missense O
mutations O
among O
the O
wasp O
gene O
lesions O
observed O
in O
boys O
with O
isolated B-Disease
thrombocytopenia I-Disease
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
was B-Disease
phenotypes O
, O
but O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
wasp O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O
. O
	
these O
findings O
, O
as O
well O
as O
the O
detection O
of O
identical O
wasp O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
lack O
of O
phenotype O
concordance O
with O
genotype O
in O
was B-Disease
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
disease O
cannot O
be O
reliably O
predicted O
solely O
on O
the O
basis O
of O
wasp O
genotypes O
. O
	
. O
	
germline O
mutations O
in O
the O
3 O
' O
part O
of O
apc B-Disease
exon O
15 O
do O
not O
result O
in O
truncated O
proteins O
and O
are O
associated O
with O
attenuated O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
. O
	
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
is O
an O
inherited O
predisposition O
to O
colorectal B-Disease
cancer I-Disease
characterized O
by O
the O
development O
of O
numerous O
adenomatous B-Disease
polyps I-Disease
predominantly O
in O
the O
colorectal O
region O
. O
	
germline O
mutations O
in O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
are O
responsible O
for O
most O
cases O
of O
fap B-Disease
. O
	
mutations O
at O
the O
5 O
end O
of O
apc B-Disease
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
the O
disease O
, O
called O
attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
( O
aapc B-Disease
) O
. O
	
we O
identified O
a O
frameshift O
mutation O
in O
the O
3 O
part O
of O
exon O
15 O
, O
resulting O
in O
a O
stop O
codon O
at O
1862 O
, O
in O
a O
large O
dutch O
kindred O
with O
aapc B-Disease
. O
	
western O
blot O
analysis O
of O
lymphoblastoid O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
previously O
reported O
swiss O
family O
carrying O
a O
frameshift O
mutation O
at O
codon O
1987 O
and O
displaying O
a O
similar O
attenuated O
phenotype O
, O
showed O
only O
the O
wild O
- O
type O
apc B-Disease
protein O
. O
	
our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
apc B-Disease
do O
not O
result O
in O
detectable O
truncated O
polypeptides O
and O
we O
hypothesize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
aapc B-Disease
phenotype O
. O
	
. O
	
complete O
genomic O
sequence O
and O
analysis O
of O
117 O
kb O
of O
human O
dna O
containing O
the O
gene O
brca1 O
. O
	
over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
brca1 O
. O
	
loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B-Disease
from O
patients O
with O
inherited O
brca1 O
mutations O
indicates O
tumor B-Disease
suppressive O
function O
. O
	
the O
low O
incidence O
of O
somatic O
mutations O
suggests O
that O
brca1 O
inactivation O
in O
sporadic O
tumors B-Disease
occurs O
by O
alternative O
mechanisms O
, O
such O
as O
interstitial O
chromosomal O
deletion O
or O
reduced O
transcription O
. O
	
to O
identify O
possible O
features O
of O
the O
brca1 O
genomic O
region O
that O
may O
contribute O
to O
chromosomal O
instability O
as O
well O
as O
potential O
transcriptional O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
dna O
sequence O
encompassing O
brca1 O
was O
obtained O
by O
random O
sequencing O
of O
four O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O
specific O
library O
. O
	
the O
24 O
exons O
of O
brca1 O
span O
an O
81 O
- O
kb O
region O
that O
has O
an O
unusually O
high O
density O
of O
alu O
repetitive O
dna O
( O
41 O
. O
	
5 O
% O
) O
, O
but O
relatively O
low O
density O
( O
4 O
. O
	
8 O
% O
) O
of O
other O
repetitive O
sequences O
. O
	
brca1 O
intron O
lengths O
range O
in O
size O
from O
403 O
bp O
to O
9 O
. O
	
2 O
kb O
and O
contain O
the O
intragenic O
microsatellite O
markers O
d17s1323 O
, O
d17s1322 O
, O
and O
d17s855 O
, O
which O
localize O
to O
introns O
12 O
, O
19 O
, O
and O
20 O
, O
respectively O
. O
	
in O
addition O
to O
brca1 O
, O
the O
contig O
contains O
two O
complete O
genes O
rho7 O
, O
a O
member O
of O
the O
rho O
family O
of O
gtp O
binding O
proteins O
, O
and O
vat1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
. O
	
partial O
sequences O
of O
the O
1a1 O
- O
3b O
b O
- O
box O
protein O
pseudogene O
and O
ifp O
35 O
, O
an O
interferon O
induced O
leucine O
zipper O
protein O
, O
reside O
within O
the O
contig O
. O
	
an O
l21 O
ribosomal O
protein O
pseudogene O
is O
embedded O
in O
brca1 O
intron O
13 O
. O
	
the O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1fp O
35 O
- O
vat1 O
- O
rho7 O
- O
brca1 O
- O
1a1 O
- O
3b O
- O
telomere O
identification O
of O
a O
ring O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
brca1 O
gene O
product O
. O
	
the O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
gene O
, O
brca1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
rich O
ring O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
. O
	
here O
we O
describe O
a O
novel O
protein O
that O
interacts O
in O
vivo O
with O
the O
n O
- O
terminal O
region O
of O
brca1 O
. O
	
this O
brca1 O
- O
associated O
ring O
domain O
( O
bard1 O
) O
protein O
contains O
an O
n O
- O
terminal O
ring O
motif O
, O
three O
tandem O
ankyrin O
repeats O
, O
and O
a O
c O
- O
terminal O
sequence O
with O
significant O
homology O
to O
the O
phylogenetically O
conserved O
brct O
domains O
that O
lie O
near O
the O
c O
terminus O
of O
brca1 O
. O
	
the O
bard1 O
/ O
brca1 O
interaction O
is O
disrupted O
by O
brca1 O
missense O
mutations O
that O
segregate O
with O
breast B-Disease
cancer I-Disease
susceptibility O
, O
indicating O
that O
bard1 O
may O
be O
involved O
in O
mediating O
tumour B-Disease
suppression O
by O
brca1 O
. O
	
. O
	
detection O
of O
heterozygous O
mutations O
in O
brca1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
. O
	
the O
ability O
to O
scan O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O
. O
	
we O
have O
designed O
high O
- O
density O
arrays O
consisting O
of O
over O
96 O
, O
600 O
oligonucleotides O
20 O
- O
nucleotides O
( O
nt O
) O
in O
length O
to O
screen O
for O
a O
wide O
range O
of O
heterozygous O
mutations O
in O
the O
3 O
. O
	
45 O
- O
kilobases O
( O
kb O
) O
exon O
11 O
of O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
gene O
brca1 O
. O
	
reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
arrays O
and O
differences O
in O
hybridization O
patterns O
quantitated O
by O
two O
- O
colour O
analysis O
. O
	
fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
identified O
in O
20 O
control O
samples O
. O
	
eight O
single O
nucleotide O
polymorphisms O
were O
also O
readily O
detected O
. O
	
dna O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
- O
throughput O
cost O
- O
efficient O
detection O
of O
genetic O
alterations O
. O
	
autosomal O
dominant O
primary O
hyperparathyroidism B-Disease
and I-Disease
jaw I-Disease
tumor I-Disease
syndrome I-Disease
associated O
with O
renal B-Disease
hamartomas I-Disease
and O
cystic B-Disease
kidney I-Disease
disease I-Disease
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B-Disease
hamartomas I-Disease
. O
	
hereditary B-Disease
hyperparathyroidism I-Disease
- I-Disease
jaw I-Disease
tumor I-Disease
syndrome I-Disease
( O
hpt B-Disease
- I-Disease
jt I-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disease I-Disease
( O
omim O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
hrpt2 O
) O
. O
	
here O
we O
report O
two O
families O
with O
hpt B-Disease
- I-Disease
jt I-Disease
syndrome I-Disease
in O
which O
adult B-Disease
renal I-Disease
hamartomas I-Disease
or O
cystic B-Disease
kidney I-Disease
disease I-Disease
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
hpt B-Disease
- I-Disease
jt I-Disease
syndrome I-Disease
. O
	
in O
the O
first O
family O
, O
renal B-Disease
lesions I-Disease
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
hpt B-Disease
and O
jt B-Disease
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
. O
	
in O
the O
second O
family O
, O
jt B-Disease
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
members O
also O
exhibited O
polycystic B-Disease
kidney I-Disease
disease I-Disease
. O
	
the O
possibility O
of O
the O
latter O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
not O
be O
ruled O
out O
. O
	
a O
sex O
- O
dependent O
penetrance O
of O
primary B-Disease
hpt I-Disease
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
in O
the O
two O
families O
. O
	
twenty O
microsatellite O
markers O
in O
the O
hrpt2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B-Disease
endocrine I-Disease
neoplasia I-Disease
( I-Disease
men I-Disease
) I-Disease
types I-Disease
1 I-Disease
and I-Disease
2 I-Disease
regions O
at O
11q13 O
and O
10q11 O
. O
	
the O
disease O
in O
these O
two O
kindreds O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
of O
- O
odds O
scores O
3 O
. O
	
2 O
- O
4 O
2 O
- O
4 O
. O
	
2 O
) O
, O
whereas O
linkage O
to O
the O
men1 B-Disease
and O
men2 B-Disease
regions O
was O
excluded O
. O
	
meiotic O
recombinations O
detected O
in O
affected O
individuals O
placed O
the O
locus O
telomeric O
of O
d1s215 O
, O
thus O
narrowing O
the O
hrpt2 O
region O
from O
> O
60 O
to O
approximately O
34 O
centimorgans O
. O
	
loss O
of O
heterozygosity O
was O
studied O
in O
seven O
renal B-Disease
hamartomas I-Disease
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B-Disease
tumor I-Disease
and O
a O
parathyroid B-Disease
tumor I-Disease
from O
the O
second O
family O
. O
	
all O
renal B-Disease
hamartomas I-Disease
showed O
loss O
of O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
region O
. O
	
the O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
a O
tumor B-Disease
suppressor O
gene O
in O
this O
region O
independent O
origin O
of O
single O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
gene O
. O
	
the O
vast O
majority O
of O
both O
polymorphic O
and O
sporadic O
g6pd O
variants O
are O
due O
to O
single O
missense O
mutations O
. O
	
in O
the O
four O
polymorphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
376 O
a O
- O
- O
> O
g O
( O
126 O
asn O
- O
- O
> O
asp O
) O
, O
which O
on O
its O
own O
gives O
rise O
to O
the O
nondeficient O
polymorphic O
variant O
, O
g6pd O
a O
. O
	
in O
a O
study O
of O
g6pd B-Disease
deficient I-Disease
patients O
who O
presented O
with O
clinical O
favism B-Disease
in O
spain O
, O
we O
have O
found O
a O
new O
polymorphic O
variant O
that O
we O
have O
called O
g6pd O
malaga O
, O
whose O
only O
abnormality O
is O
a O
542 O
a O
- O
- O
> O
t O
( O
181 O
asp O
- O
- O
> O
val O
) O
mutation O
. O
	
this O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
g6pd O
a O
in O
the O
double O
mutant O
, O
g6pd O
santamaria O
. O
	
g6pd O
malaga O
is O
associated O
with O
enzyme B-Disease
deficiency I-Disease
( O
class O
iii O
) O
, O
and O
the O
enzymic O
properties O
of O
g6pd O
malaga O
and O
g6pd O
santamaria O
are O
quite O
similar O
, O
indicating O
that O
in O
this O
case O
the O
effects O
of O
the O
two O
mutations O
are O
additive O
rather O
than O
synergistic O
. O
	
g6pd O
santamaria O
might O
have O
been O
produced O
by O
recombination O
between O
g6pd O
a O
and O
g6pd O
malaga O
; O
however O
haplotype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
polymorphism O
, O
suggests O
that O
the O
same O
542 O
a O
- O
- O
> O
t O
mutation O
has O
taken O
place O
independently O
in O
a O
g6pd O
b O
gene O
to O
give O
g6pd O
malaga O
and O
in O
a O
g6pd O
a O
gene O
to O
give O
g6pd O
santamaria O
. O
	
these O
findings O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
g6pd O
locus O
. O
	
. O
	
brca1 O
r841w O
: O
a O
strong O
candidate O
for O
a O
common O
mutation O
with O
moderate O
phenotype O
. O
	
brca1 O
mutations O
cause O
increased O
risk O
for O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
frequently O
of O
early O
onset O
. O
	
many O
different O
mutations O
occur O
in O
brca1 O
, O
including O
several O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
for O
a O
significant O
number O
of O
families O
with O
heritable O
cancer B-Disease
predisposition O
. O
	
these O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
brca1 O
lesion O
. O
	
we O
report O
a O
novel O
missense O
change O
in O
brca1 O
, O
2640 O
c O
- O
- O
> O
t O
( O
r841w O
) O
, O
found O
in O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
breast B-Disease
and I-Disease
79 I-Disease
ovarian I-Disease
cancer I-Disease
cases O
from O
orange O
county O
, O
ca O
. O
	
these O
are O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O
history O
. O
	
in O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast B-Disease
, I-Disease
ovarian I-Disease
, I-Disease
or I-Disease
other I-Disease
cancers I-Disease
possibly O
related O
to O
a O
brca1 O
defect O
and O
family O
members O
showed O
a O
high O
concordance O
of O
cancer B-Disease
incidence O
with O
the O
presence O
of O
r841w O
. O
	
the O
age O
of O
cancer B-Disease
onset O
was O
not O
always O
distinct O
from O
typical O
sporadic O
cases O
. O
	
testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
r841w O
might O
be O
a O
rare O
polymorphism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B-Disease
cancer I-Disease
diagnosed O
at O
age O
77 O
years O
, O
and O
cancer B-Disease
in O
one O
parent O
. O
	
r841w O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
	
7 O
% O
) O
of O
all O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
in O
this O
population O
. O
	
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
: O
founder O
effect O
among O
north O
african O
jews O
. O
	
the O
atm O
gene O
is O
responsible O
for O
the O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
characterized O
by O
cerebellar B-Disease
degeneration I-Disease
, O
immunodeficiency B-Disease
and O
cancer B-Disease
predisposition I-Disease
. O
	
a B-Disease
- I-Disease
t I-Disease
carriers O
were O
reported O
to O
be O
moderately O
cancer B-Disease
- I-Disease
prone I-Disease
. O
	
a O
wide O
variety O
of O
a B-Disease
- I-Disease
t I-Disease
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
. O
	
however O
, O
a O
single O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
atm O
alleles O
in O
jewish O
a B-Disease
- I-Disease
t I-Disease
families O
of O
north O
african O
origin O
, O
coming O
from O
various O
regions O
of O
morocco O
and O
tunisia O
. O
	
this O
mutation O
, O
103c O
- O
- O
> O
t O
, O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
the O
atm O
protein O
. O
	
in O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
atm O
protein O
failed O
to O
defect O
this O
protein O
in O
patient O
cells O
. O
	
a O
rapid O
carrier O
detection O
assay O
detected O
this O
mutation O
in O
three O
out O
of O
488 O
atm O
alleles O
of O
jewish O
moroccan O
or O
tunisian O
origin O
. O
	
this O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
a B-Disease
- I-Disease
t I-Disease
carriers O
in O
a O
large O
jewish O
community O
. O
	
. O
	
mutation O
analysis O
of O
brca1 O
and O
brca2 O
in O
a O
male B-Disease
breast I-Disease
cancer I-Disease
population O
. O
	
a O
population O
- O
based O
series O
of O
54 O
male B-Disease
breast I-Disease
cancer I-Disease
cases O
from O
southern O
california O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the O
inherited B-Disease
breast I-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
genes O
, O
brca1 O
and O
brca2 O
. O
	
nine O
( O
17 O
% O
) O
of O
the O
patients O
had O
a O
family O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
in O
at O
least O
one O
first O
- O
degree O
relative O
. O
	
a O
further O
seven O
( O
13 O
% O
) O
of O
the O
patients O
reported O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
in O
at O
least O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O
	
no O
germ O
- O
line O
brca1 O
mutations O
were O
found O
. O
	
two O
male B-Disease
breast I-Disease
cancer I-Disease
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
mutations O
in O
the O
brca2 O
gene O
. O
	
only O
one O
of O
the O
two O
male B-Disease
breast I-Disease
cancer I-Disease
patients O
carrying O
a O
brca2 O
mutation O
had O
a O
family O
history O
of O
cancer B-Disease
, O
with O
one O
case O
of O
ovarian B-Disease
cancer I-Disease
in O
a O
first O
- O
degree O
relative O
. O
	
the O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B-Disease
breast I-Disease
cancer I-Disease
with O
a O
family O
history O
of O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
brca1 O
gene O
or O
the O
brca2 O
gene O
. O
	
. O
	
molecular O
basis O
for O
duarte B-Disease
and I-Disease
los I-Disease
angeles I-Disease
variant I-Disease
galactosemia I-Disease
. O
	
human O
orythrocytes O
that O
are O
homozygous O
for O
the O
duarte B-Disease
enzyme I-Disease
variant I-Disease
of I-Disease
galactosemia I-Disease
( O
d O
/ O
d O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focusing O
and O
50 O
% O
reduction O
in O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
galt O
) O
enzyme O
activity O
. O
	
the O
duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
n314d O
/ O
n314d O
. O
	
the O
characteristic O
duarte O
isoform O
is O
also O
associated O
with O
a O
variant O
called O
the O
los O
angeles O
( O
la O
) O
phenotype O
, O
which O
has O
increased O
galt O
enzyme O
activity O
. O
	
we O
evaluated O
galt O
enzyme O
activity O
and O
screened O
the O
galt O
genes O
of O
145 O
patients O
with O
one O
or O
more O
n314d O
- O
containing O
alleles O
. O
	
we O
found O
seven O
with O
the O
la O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721c O
- O
- O
> O
t O
transition O
in O
exon O
7 O
in O
cis O
with O
the O
n314d O
missense O
mutation O
. O
	
the O
1721c O
- O
- O
> O
t O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
at O
amino O
acid O
218 O
( O
l218l O
) O
. O
	
in O
pedigree O
analyses O
, O
this O
1721c O
- O
- O
> O
t O
transition O
segregated O
with O
the O
la O
phenotype O
of O
increased O
galt O
activity O
in O
three O
different O
biochemical O
phenotypes O
( O
la O
/ O
n O
, O
la O
/ O
g O
, O
and O
la O
/ O
d O
) O
. O
	
to O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
la O
variant O
, O
we O
compared O
galt O
mrna O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
stability O
in O
lymphoblast O
cell O
lines O
of O
d O
and O
la O
phenotypes O
with O
comparable O
genotypes O
. O
	
galt O
protein O
abundance O
was O
increased O
in O
la O
compared O
to O
d O
alleles O
, O
but O
mrna O
was O
similar O
among O
all O
genotypes O
. O
	
when O
la O
/ O
d O
and O
d O
/ O
d O
galt O
biochemical O
phenotypes O
were O
compared O
to O
n O
/ O
n O
galt O
phenotypes O
, O
both O
had O
50 O
% O
, O
as O
compared O
to O
21 O
% O
, O
reduction O
in O
galt O
activity O
in O
the O
wild O
type O
( O
n O
/ O
n O
) O
after O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
degrees O
c O
for O
15 O
min O
. O
	
we O
conclude O
that O
the O
codon O
change O
n314d O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721c O
- O
- O
> O
t O
produces O
the O
la B-Disease
variant I-Disease
of I-Disease
galactosemia I-Disease
and O
that O
this O
nucleotide O
change O
increases O
galt O
activity O
by O
increasing O
galt O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O
thermal O
lability O
. O
	
a O
favorable O
codon O
bias O
for O
the O
mutated O
codon O
with O
consequently O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
. O
	
. O
	
the O
tsg101 O
tumor B-Disease
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B-Disease
cancer I-Disease
. O
	
recent O
work O
has O
identified O
a O
mouse O
gene O
( O
tsg101 O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
and O
the O
ability O
to O
produce O
metastatic B-Disease
tumors I-Disease
in O
nude O
mice O
. O
	
here O
, O
we O
report O
that O
the O
human O
homolog O
, O
tsg101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
11 O
, O
bands O
15 O
. O
	
1 O
- O
15 O
1 O
- O
15 O
. O
	
2 O
, O
a O
region O
proposed O
to O
contain O
tumor B-Disease
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
frequency O
in O
human O
breast B-Disease
cancer I-Disease
. O
	
in O
7 O
of O
15 O
uncultured O
primary O
human O
breast B-Disease
carcinomas I-Disease
, O
intragenic O
deletions O
were O
shown O
in O
tsg101 O
genomic O
dna O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
tsg101 O
alleles O
were O
identified O
in O
four O
of O
these O
cancers B-Disease
. O
	
no O
tsg101 O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the O
breast B-Disease
cancer I-Disease
patients O
. O
	
these O
findings O
strongly O
implicate O
tsg101 O
mutations O
in O
human O
breast B-Disease
cancer I-Disease
moderate O
intergenerational O
and O
somatic O
instability O
of O
a O
55 O
- O
ctg O
repeat O
in O
transgenic O
mice O
. O
	
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
ctg O
) O
n O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
( O
utr O
) O
of O
the O
dm B-Disease
protein O
kinase O
gene O
( O
dmpk O
) O
. O
	
the O
( O
ctg O
) O
n O
repeat O
is O
polymorphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
unaffected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
ctgs O
. O
	
the O
size O
of O
the O
( O
ctg O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
clinical O
severity O
and O
age O
of O
onset O
. O
	
the O
instability O
of O
the O
ctg O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O
	
moreover O
, O
mitotic O
instability O
analysis O
of O
different O
human O
dm B-Disease
tissues O
shows O
length O
mosaicism O
between O
different O
cell O
lineages O
. O
	
the O
molecular O
mechanisms O
of O
triplet O
instability O
remain O
elusive O
. O
	
to O
investigate O
the O
role O
of O
genomic O
sequences O
in O
instability O
, O
we O
produced O
transgenic O
mice O
containing O
a O
45 O
- O
kb O
genomic O
segment O
with O
a O
55 O
- O
ctg O
repeat O
cloned O
from O
a O
mildly O
affected O
patient O
. O
	
in O
contrast O
to O
other O
mouse O
models O
containing O
cag O
repeats O
within O
cdnas O
, O
these O
mice O
showed O
both O
intergenerational O
and O
somatic O
repeat O
instability O
. O
	
. O
	
missense O
mutations O
in O
the O
fas O
gene O
resulting O
in O
autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
: O
a O
molecular O
and O
immunological O
analysis O
. O
	
programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
homeostatic O
maintenance O
of O
the O
immune O
system O
. O
	
the O
fas O
/ O
apo O
- O
1 O
receptor O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
apoptosis O
, O
as O
demonstrated O
by O
lymphoproliferation O
in O
mrl O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently O
described O
autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
( O
alps B-Disease
) O
in O
humans O
, O
both O
of O
which O
are O
due O
to O
mutations O
in O
the O
fas O
gene O
. O
	
we O
describe O
a O
novel O
family O
with O
alps B-Disease
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
on O
both O
the O
fas O
gene O
alleles O
and O
show O
lack O
of O
fas O
- O
induced O
apoptosis O
. O
	
the O
children O
share O
common O
clinical O
features O
including O
splenomegaly B-Disease
and O
lymphadenopathy B-Disease
, O
but O
only O
one O
developed O
severe O
autoimmune B-Disease
manifestations I-Disease
. O
	
in O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
anergic O
cd3 O
+ O
cd4 O
- O
cd8 O
- O
( O
double O
negative O
, O
[ O
dn O
] O
) O
t O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
hla O
- O
dr O
expression O
on O
peripheral O
cd3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
receptor O
( O
sll O
- O
2r O
) O
and O
soluble O
cd30 O
( O
scd30 O
) O
. O
	
. O
	
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
following O
genome O
damage O
. O
	
the O
product O
of O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
gene O
( O
atm O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
to O
a O
peptide O
corresponding O
to O
the O
deduced O
amino O
acid O
sequence O
. O
	
the O
atm O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
peripheral O
blood O
lymphocytes O
. O
	
atm O
protein O
levels O
and O
localization O
remain O
constant O
throughout O
all O
stages O
of O
the O
cell O
cycle O
. O
	
truncated O
atm O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
patients O
homozygous O
for O
mutations O
leading O
to O
premature O
protein O
termination O
. O
	
exposure O
of O
normal O
human O
cells O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
drug O
neocarzinostatin O
had O
no O
effect O
on O
atm O
protein O
levels O
, O
in O
contrast O
to O
a O
noted O
rise O
in O
p53 O
levels O
over O
the O
same O
time O
interval O
. O
	
these O
findings O
are O
consistent O
with O
a O
role O
for O
the O
atm O
protein O
in O
ensuring O
the O
fidelity O
of O
dna O
repair O
and O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
	
. O
	
type O
iii O
collagen O
is O
crucial O
for O
collagen O
i O
fibrillogenesis O
and O
for O
normal O
cardiovascular O
development O
. O
	
type O
iii O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
iii O
) O
chains O
and O
is O
expressed O
in O
early O
embryos O
and O
throughout O
embryogenesis O
. O
	
in O
the O
adult O
, O
type O
iii O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
variety O
of O
internal O
organs O
and O
skin O
. O
	
mutations O
in O
the O
col3a1 O
gene O
have O
been O
implicated O
as O
a O
cause O
of O
type B-Disease
iv I-Disease
ehlers I-Disease
- I-Disease
danlos I-Disease
syndrome I-Disease
, O
a O
disease O
leading O
to O
aortic B-Disease
rupture I-Disease
in O
early O
adult O
life O
. O
	
to O
directly O
study O
the O
role O
of O
col3a1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
col3a1 O
gene O
in O
embryonic O
stem O
cells O
by O
homologous O
recombination O
. O
	
the O
mutated O
allele O
was O
transmitted O
through O
the O
mouse O
germ O
line O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
intercrosses O
. O
	
about O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
compared O
with O
wild O
- O
type O
mice O
. O
	
the O
major O
cause O
of O
death O
of O
mutant O
mice O
was O
rupture O
of O
the O
major O
blood O
vessels O
, O
similar O
to O
patients O
with O
type B-Disease
iv I-Disease
ehlers I-Disease
- I-Disease
danlos I-Disease
syndrome I-Disease
. O
	
ultrastructural O
analysis O
of O
tissues O
from O
mutant O
mice O
revealed O
that O
type O
iii O
collagen O
is O
essential O
for O
normal O
collagen O
i O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O
organs O
. O
	
. O
	
nonsense O
mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
plp O
) O
in O
a O
family O
with O
an O
unusual O
form O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O
	
we O
report O
a O
g O
- O
- O
> O
a O
transition O
at O
nucleotide O
431 O
of O
the O
proteolipid O
protein O
gene O
( O
plp O
) O
results O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
an O
unusual O
form O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
pmd B-Disease
) O
. O
	
the O
mutation O
, O
which O
creates O
a O
second O
alui O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
plp O
. O
	
the O
clinical O
picture O
resembles O
somewhat O
that O
of O
x B-Disease
- I-Disease
linked I-Disease
spastic I-Disease
paraplegia I-Disease
( O
spg B-Disease
) O
. O
	
it O
differs O
from O
this O
and O
both O
the O
classical O
and O
connatal O
forms O
of O
pmd B-Disease
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B-Disease
is O
absent O
, O
tremors B-Disease
are O
prominent O
, O
mental B-Disease
retardation I-Disease
is O
not O
severe O
, O
some O
patients O
show O
dementia B-Disease
or O
personality B-Disease
disorders I-Disease
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
. O
	
the O
nonsense O
mutation O
, O
which O
is O
in O
exon O
3b O
, O
should O
block O
the O
synthesis O
of O
normal O
plp O
but O
spare O
dm20 O
, O
the O
isoform O
whose O
persistence O
has O
been O
associated O
with O
mild O
forms O
of O
plp B-Disease
- I-Disease
associated I-Disease
disease I-Disease
in O
both O
humans O
and O
mice O
. O
	
. O
	
common O
brca1 O
variants O
and O
susceptibility O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
in O
the O
general O
population O
. O
	
most O
multiple O
case O
families O
of O
young O
onset O
breast B-Disease
cancer I-Disease
and O
ovarian B-Disease
cancer I-Disease
are O
thought O
to O
be O
due O
to O
highly O
penetrant O
mutations O
in O
the O
predisposing O
genes O
brca1 O
and O
brca2 O
. O
	
however O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
of O
all O
breast B-Disease
cancer I-Disease
incidence O
. O
	
a O
much O
larger O
fraction O
of O
breast B-Disease
cancer I-Disease
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
confer O
more O
modest O
individual O
risks O
. O
	
there O
are O
several O
common O
polymorphisms O
in O
the O
brca1 O
gene O
which O
generate O
amino O
acid O
substitutions O
. O
	
we O
have O
examined O
the O
frequency O
of O
four O
of O
these O
polymorphisms O
gln356arg O
, O
pro871leu O
, O
glu1038gly O
and O
ser1613gly O
in O
large O
series O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
cases O
and O
matched O
controls O
. O
	
due O
to O
strong O
linkage O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
three O
haplotypes O
with O
a O
frequency O
> O
1 O
. O
	
3 O
% O
. O
	
the O
most O
common O
haplotypes O
, O
defined O
by O
the O
alleles O
gln356pro871glu1038ser1613 O
and O
gln356leu871gly1038gly1613 O
, O
have O
frequencies O
of O
0 O
. O
	
57 O
and O
0 O
. O
	
32 O
respectively O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
. O
	
thus O
the O
most O
common O
polymorphisms O
of O
the O
brca1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
risk O
. O
	
however O
, O
our O
data O
suggest O
that O
the O
arg356 O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B-Disease
cancer I-Disease
patients O
from O
that O
in O
controls O
( O
arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
p O
= O
0 O
. O
	
01 O
) O
, O
indicating O
that O
it O
may O
be O
protective O
against O
breast B-Disease
cancer I-Disease
. O
	
if O
this O
finding O
can O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
the O
structural O
features O
of O
the O
brca1 O
protein O
that O
are O
important O
for O
its O
function O
. O
	
kniest B-Disease
dysplasia I-Disease
: O
dr O
. O
	
w O
. O
	
kniest O
, O
his O
patient O
, O
the O
molecular O
defect O
. O
	
kniest B-Disease
dysplasia I-Disease
is O
a O
severe O
chondrodysplasia B-Disease
caused O
by O
the O
defective B-Disease
formation I-Disease
of I-Disease
type I-Disease
ii I-Disease
collagen I-Disease
. O
	
we O
report O
about O
dr O
. O
	
kniest O
, O
who O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B-Disease
handicapped I-Disease
with O
short B-Disease
stature I-Disease
, O
restricted B-Disease
joint I-Disease
mobility I-Disease
, O
and O
blindness B-Disease
but O
is O
mentally O
alert O
and O
leads O
an O
active O
life O
. O
	
molecular O
analysis O
of O
the O
patients O
dna O
showed O
a O
single O
base O
( O
g O
) O
deletion O
involving O
the O
gt O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destroying O
a O
splice O
site O
of O
the O
col2a1 O
gene O
. O
	
this O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
kniest B-Disease
dysplasia I-Disease
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
exon O
skipping O
as O
a O
result O
of O
col2a1 O
splice O
site O
mutations O
. O
	
. O
	
cloning O
of O
the O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
the O
key O
enzyme O
of O
alkaptonuria B-Disease
in O
mouse O
. O
	
we O
determined O
48 O
amino O
acid O
residues O
from O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
hgo O
; O
e O
. O
	
c O
. O
	
1 O
. O
	
13 O
. O
	
11 O
. O
	
15 O
) O
of O
mouse O
liver O
. O
	
after O
digestion O
with O
trypsin O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O
amino O
acid O
sequenced O
. O
	
the O
deduced O
codon O
sequence O
of O
three O
peptides O
was O
used O
to O
derive O
degenerated O
oligomeres O
. O
	
by O
combining O
these O
oligos O
, O
we O
were O
able O
to O
amplify O
fragments O
from O
100 O
to O
300 O
bases O
( O
b O
) O
from O
mouse O
liver O
cdna O
by O
polymerase O
chain O
reaction O
after O
reverse O
transcription O
( O
rt O
- O
pcr O
) O
. O
	
a O
fragment O
of O
200 O
b O
was O
cloned O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
cdna O
library O
. O
	
one O
clone O
from O
this O
library O
contained O
the O
complete O
cdna O
- O
insert O
for O
hgo O
as O
determined O
by O
sequencing O
. O
	
the O
cdna O
encodes O
for O
a O
protein O
of O
50 O
kda O
, O
as O
predicted O
. O
	
the O
cdna O
of O
mouse O
hgo O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
hmga O
from O
aspergillus O
. O
	
sequence O
similarities O
to O
human O
expressed O
sequence O
tags O
( O
est O
) O
clones O
ranged O
from O
70 O
% O
to O
20 O
% O
. O
	
the O
positions O
of O
122 O
conserved O
amino O
acids O
could O
be O
determined O
by O
multiple O
sequence O
alignment O
. O
	
we O
identified O
one O
first O
intron O
of O
928 O
b O
in O
the O
mouse O
gene O
. O
	
the O
gene O
for O
hgo O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
rt O
- O
pcr O
on O
different O
cdnas O
. O
	
fish O
experiments O
with O
the O
whole O
murine O
cdna O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
chromosomal O
band O
3q13 O
. O
	
3 O
- O
q21 O
. O
	
this O
corresponds O
well O
to O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
human O
alkaptonuria B-Disease
gene O
( O
aku O
) O
to O
the O
same O
chromosomal O
region O
by O
multipoint O
linkage O
analysis O
. O
	
we O
therefore O
conclude O
that O
the O
hgo O
cdna O
encodes O
the O
gene O
responsible O
for O
alkaptonuria B-Disease
. O
	
pten O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B-Disease
, I-Disease
breast I-Disease
, I-Disease
and I-Disease
prostate I-Disease
cancer I-Disease
. O
	
mapping O
of O
homozygous O
deletions O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate O
tumor B-Disease
suppressor O
gene O
, O
pten O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human O
cancers B-Disease
. O
	
in O
preliminary O
screens O
, O
mutations O
of O
pten O
were O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma B-Disease
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate B-Disease
cancer I-Disease
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B-Disease
cancer I-Disease
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B-Disease
glioblastomas I-Disease
. O
	
the O
predicted O
pten O
product O
has O
a O
protein O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
to O
tensin O
, O
a O
protein O
that O
interacts O
with O
actin O
filaments O
at O
focal O
adhesions O
. O
	
these O
homologies O
suggest O
that O
pten O
may O
suppress O
tumor B-Disease
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may O
regulate O
tumor B-Disease
cell O
invasion O
and O
metastasis B-Disease
through O
interactions O
at O
focal O
adhesions O
. O
	
. O
	
heterogeneity O
in O
schwartz B-Disease
- I-Disease
jampel I-Disease
chondrodystrophic I-Disease
myotonia I-Disease
. O
	
the O
schwartz B-Disease
- I-Disease
jampel I-Disease
syndrome I-Disease
( O
sjs B-Disease
; O
chondrodystrophic B-Disease
myotonia I-Disease
; O
mck O
255 O
, O
800 O
) O
is O
a O
recessively B-Disease
inherited I-Disease
condition I-Disease
defined O
by O
myotonia B-Disease
, O
short B-Disease
stature I-Disease
, O
and O
bone B-Disease
dysplasia I-Disease
. O
	
genetic O
linkage O
between O
sjs B-Disease
and O
chromosomal O
region O
1q36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
, O
but O
the O
gene O
has O
not O
yet O
been O
identified O
. O
	
we O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
to O
identify O
distinct O
subgroups O
. O
	
in O
addition O
, O
we O
tested O
genetic O
linkage O
to O
the O
sjs B-Disease
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
two O
affected O
sibs O
. O
	
we O
found O
that O
a O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of O
myotonia B-Disease
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary O
bone B-Disease
dysplasia I-Disease
with O
myotonia B-Disease
. O
	
within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
clinical O
course O
and O
pattern O
of O
bone O
changes O
. O
	
we O
tentatively O
isolate O
three O
different O
types O
of O
sjs B-Disease
type I-Disease
1a I-Disease
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B-Disease
dysplasia I-Disease
, O
corresponding O
to O
the O
original O
descriptions O
of O
schwartz O
, O
jampel O
and O
aberfeld O
; O
type O
1b O
, O
similar O
to O
type O
1a O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B-Disease
dysplasia I-Disease
resembling O
kniest B-Disease
dysplasia I-Disease
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B-Disease
dysplasia I-Disease
resembling O
pyle B-Disease
disease I-Disease
. O
	
genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
sjs B-Disease
type I-Disease
2 I-Disease
showed O
evidence O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O
	
conclusions O
sjs B-Disease
is O
clinically O
and O
radiologically O
heterogeneous O
. O
	
the O
causes O
of O
heterogeneity O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
sjs B-Disease
locus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
sjs B-Disease
locus O
. O
	
a O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
genotype O
- O
phenotype O
correlations O
. O
	
. O
	
a O
clinical O
overview O
of O
wt1 O
gene O
mutations O
. O
	
mutations O
in O
the O
wt1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B-Disease
cancer I-Disease
, O
wilms B-Disease
tumour I-Disease
( O
wt B-Disease
) O
. O
	
six O
years O
on O
, O
we O
review O
100 O
reports O
of O
intragenic O
wt1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
phenotypes O
. O
	
while O
only O
5 O
% O
of O
sporadic B-Disease
wilms I-Disease
tumours I-Disease
have O
intragenic O
wt1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
( O
renal B-Disease
nephropathy I-Disease
, O
gonadal B-Disease
anomaly I-Disease
, O
predisposition B-Disease
to I-Disease
wt I-Disease
) O
carry O
constitutional O
intragenic O
wt1 O
mutations O
. O
	
wt1 O
mutations O
have O
also O
been O
reported O
in O
juvenile B-Disease
granulosa I-Disease
cell I-Disease
tumour I-Disease
, O
non B-Disease
- I-Disease
asbestos I-Disease
related I-Disease
mesothelioma I-Disease
, O
desmoplastic B-Disease
small I-Disease
round I-Disease
cell I-Disease
tumour I-Disease
and O
, O
most O
recently O
, O
acute B-Disease
myeloid I-Disease
leukemia I-Disease
. O
	
. O
	
a O
mutation O
in O
autosomal B-Disease
dominant I-Disease
myotonia I-Disease
congenita I-Disease
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
. O
	
autosomal B-Disease
dominant I-Disease
myotonia I-Disease
congenita I-Disease
is O
an O
inherited B-Disease
disorder I-Disease
of I-Disease
skeletal I-Disease
muscle I-Disease
caused O
by O
mutations O
in O
a O
voltage O
- O
gated O
cl O
- O
channel O
gene O
( O
clcn1 O
, O
7q35 O
) O
. O
	
here O
, O
we O
report O
that O
a O
mutation O
predicting O
the O
substitution O
of O
gly O
230 O
by O
glutamic O
acid O
( O
g230e O
) O
between O
segments O
d3 O
and O
d4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
cl O
- O
channel O
( O
hcic O
- O
1 O
) O
expressed O
in O
a O
mammalian O
cell O
line O
( O
tsa201 O
) O
. O
	
the O
g230e O
mutation O
causes O
substantial O
changes O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
fundamental O
change O
in O
rectification O
of O
the O
current O
- O
voltage O
relationship O
. O
	
whereas O
wild O
- O
type O
channels O
are O
characterized O
by O
pronounced O
inward O
rectification O
and O
a O
cl O
> O
thiocyanate O
> O
br O
> O
no O
( O
3 O
) O
> O
i O
> O
ch O
( O
3 O
) O
so O
( O
3 O
) O
selectivity O
, O
g230e O
exhibits O
outward O
rectification O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
no O
( O
3 O
) O
> O
i O
> O
br O
> O
cl O
> O
ch O
( O
3 O
) O
so O
( O
3 O
) O
selectivity O
. O
	
furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
of O
the O
wild O
- O
type O
channel O
. O
	
voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
the O
hclc O
- O
1 O
conduction O
pathway O
. O
	
both O
binding O
sites O
are O
preserved O
in O
the O
mutant O
but O
have O
decreased O
affinities O
for O
iodide O
. O
	
these O
findings O
suggest O
that O
gly O
230 O
is O
critical O
for O
normal O
ion O
conductance O
in O
hclc O
- O
1 O
and O
that O
this O
residue O
resides O
within O
the O
channel O
pore O
. O
	
. O
	
the O
incidence O
of O
pax6 O
mutation O
in O
patients O
with O
simple O
aniridia B-Disease
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
cases O
. O
	
twelve O
aniridia B-Disease
patients O
, O
five O
with O
a O
family O
history O
and O
seven O
presumed O
to O
be O
sporadic O
, O
were O
exhaustively O
screened O
in O
order O
to O
test O
what O
proportion O
of O
people O
with O
aniridia B-Disease
, O
uncomplicated O
by O
associated O
anomalies O
, O
carry O
mutations O
in O
the O
human O
pax6 O
gene O
. O
	
mutations O
were O
detected O
in O
90 O
% O
of O
the O
cases O
. O
	
three O
mutation O
detection O
techniques O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
. O
	
the O
protein O
truncation O
test O
( O
ptt O
) O
was O
used O
on O
rt O
- O
pcr O
products O
, O
sscp O
on O
genomic O
pcr O
amplifications O
, O
and O
chemical O
cleavage O
of O
mismatch O
on O
both O
rt O
- O
pcr O
and O
genomic O
amplifications O
. O
	
for O
rt O
- O
pcr O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
. O
	
on O
genomic O
products O
exons O
1 O
to O
13 O
( O
including O
740 O
bp O
of O
the O
3 O
untranslated O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
specific O
enhancer O
in O
intron O
4 O
. O
	
ten O
of O
the O
possible O
12 O
mutations O
in O
the O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
were O
found O
, O
all O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
. O
	
five O
were O
splice O
site O
mutations O
( O
one O
in O
the O
donor O
site O
of O
intron O
4 O
, O
two O
in O
the O
donor O
site O
of O
intron O
6 O
, O
one O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
and O
9 O
) O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
, O
9 O
, O
10 O
, O
11 O
, O
and O
12 O
. O
	
sscp O
analysis O
of O
individually O
amplified O
exons O
, O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
seen O
, O
was O
the O
most O
useful O
detection O
method O
for O
pax6 O
. O
	
. O
	
insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
in O
japanese O
. O
	
in O
the O
caucasian O
population O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
ins O
) O
region O
contains O
the O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
locus O
( O
iddm2 O
) O
. O
	
in O
the O
japanese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
iddm2 O
to O
the O
pathogenesis O
of O
iddm B-Disease
. O
	
we O
conducted O
an O
association O
study O
of O
iddm B-Disease
in O
a O
large O
number O
of O
japanese O
subjects O
with O
multiple O
polymorphisms O
in O
ins O
region O
. O
	
we O
found O
a O
significant O
association O
of O
the O
ins O
region O
with O
iddm B-Disease
. O
	
alleles O
positively O
associated O
with O
iddm B-Disease
in O
ins O
region O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
iddm B-Disease
in O
caucasian O
population O
, O
although O
positively O
- O
associated O
alleles O
are O
very O
common O
( O
allele O
frequencies O
> O
0 O
. O
	
9 O
) O
in O
the O
japanese O
general O
population O
. O
	
these O
data O
suggest O
that O
iddm2 O
is O
involved O
in O
the O
genetic O
susceptibility O
to O
iddm B-Disease
in O
japanese O
. O
	
the O
high O
frequencies O
of O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
that O
iddm2 O
locus O
is O
not O
responsible O
for O
the O
low O
incidence O
of O
iddm B-Disease
in O
japanese O
. O
	
the O
human O
complement O
c9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
structure O
. O
	
the O
ninth O
component O
of O
human O
complement O
( O
c9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
the O
membrane O
attack O
complex O
. O
	
c9 O
is O
a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
5p O
. O
	
deficiency B-Disease
of I-Disease
terminal I-Disease
complement I-Disease
components I-Disease
is O
generally O
associated O
with O
recurrent O
neisseria B-Disease
infections I-Disease
. O
	
we O
studied O
a O
previously O
described O
swiss O
family O
with O
inherited B-Disease
c9 I-Disease
deficiency I-Disease
. O
	
to O
identify O
the O
genetic O
basis O
of O
c9 B-Disease
deficiency I-Disease
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
pcr O
and O
direct O
dna O
sequencing O
. O
	
as O
a O
cause O
of O
c9 B-Disease
deficiency I-Disease
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
tga O
stop O
codons O
in O
the O
coding O
sequence O
. O
	
one O
mutation O
, O
a O
c O
to O
a O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cdna O
position O
166 O
, O
the O
other O
, O
a O
c O
to O
t O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cdna O
position O
464 O
) O
. O
	
in O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
c9 B-Disease
deficiency I-Disease
, O
we O
demonstrated O
that O
the O
two O
mutations O
are O
segregating O
independently O
. O
	
therefore O
, O
these O
mutations O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
probands O
studied O
. O
	
dna O
sequencing O
of O
the O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
exons O
10 O
and O
11 O
. O
	
no O
additional O
introns O
were O
detected O
in O
exons O
6 O
and O
10 O
. O
	
furthermore O
, O
dna O
marker O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
c6 O
, O
c7 O
, O
and O
c9 O
genes O
, O
confirming O
the O
linkage O
of O
the O
observed O
c9 O
mutations O
with O
defined O
haplotypes O
. O
	
. O
	
brca1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
the O
risk O
of O
breast B-Disease
cancer I-Disease
. O
	
background O
to O
define O
the O
incidence O
of O
brca1 O
mutations O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B-Disease
cancer I-Disease
, O
we O
analyzed O
dna O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
brca1 O
mutation O
in O
individual O
families O
. O
	
methods O
clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
dna O
analysis O
were O
obtained O
from O
263 O
women O
with O
breast B-Disease
cancer I-Disease
. O
	
conformation O
- O
sensitive O
gel O
electrophoresis O
and O
dna O
sequencing O
were O
used O
to O
identify O
brca1 O
mutations O
. O
	
results O
brca1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B-Disease
cancer I-Disease
. O
	
only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B-Disease
cancer I-Disease
but O
not O
ovarian B-Disease
cancer I-Disease
had O
brca1 O
mutations O
. O
	
the O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O
	
among O
family O
members O
, O
an O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
diagnosis O
of O
breast B-Disease
cancer I-Disease
, O
the O
presence O
of O
ovarian B-Disease
cancer I-Disease
, O
the O
presence O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
in O
the O
same O
woman O
, O
and O
ashkenazi O
jewish O
ancestry O
were O
all O
associated O
with O
an O
increased O
risk O
of O
detecting O
a O
brca1 O
mutation O
. O
	
no O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B-Disease
cancer I-Disease
or O
the O
number O
of O
breast B-Disease
cancers I-Disease
in O
a O
family O
and O
the O
detection O
of O
a O
brca1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
the O
brca1 O
gene O
and O
the O
presence O
of O
ovarian B-Disease
cancer I-Disease
in O
a O
family O
. O
	
conclusions O
among O
women O
with O
breast B-Disease
cancer I-Disease
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
brca1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
linkage O
analysis O
. O
	
these O
results O
suggest O
that O
even O
in O
a O
referral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
brca1 O
mutations O
will O
be O
negative O
and O
therefore O
uninformative O
. O
	
. O
	
mutations O
in O
the O
arginine O
- O
rich O
protein O
gene O
( O
arp O
) O
in O
pancreatic B-Disease
cancer I-Disease
. O
	
the O
arp O
gene O
encodes O
a O
highly O
conserved O
arginine O
- O
rich O
protein O
from O
chromosomal O
band O
3p21 O
. O
	
1 O
1 O
. O
	
at O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B-Disease
tumors I-Disease
, O
although O
not O
in O
pancreatic B-Disease
cancer I-Disease
. O
	
we O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
atg50 O
- O
- O
> O
agg O
) O
or O
deletion O
of O
codon O
50 O
of O
the O
arp O
gene O
in O
different O
tumor B-Disease
types I-Disease
( O
shridhar O
et O
al O
. O
	
, O
1996 O
, O
1996a O
) O
. O
	
in O
the O
present O
study O
, O
we O
have O
observed O
mutations O
involving O
codon O
50 O
in O
11 O
of O
37 O
pancreatic B-Disease
tumors I-Disease
. O
	
the O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic B-Disease
tumors I-Disease
as O
in O
the O
other O
types O
of O
tumors B-Disease
previously O
examined O
. O
	
in O
addition O
, O
we O
have O
detected O
mutations O
at O
codon O
51 O
in O
multiple O
pcr O
subclones O
in O
two O
other O
pancreatic B-Disease
tumors I-Disease
. O
	
mutations O
in O
the O
arp O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic B-Disease
cancer I-Disease
, O
as O
well O
as O
many O
other O
cancers B-Disease
. O
	
difficulties O
in O
the O
ascertainment O
of O
c9 B-Disease
deficiency I-Disease
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
c9 B-Disease
- I-Disease
deficient I-Disease
subject O
. O
	
a O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
for O
complement O
function O
using O
haemolytic O
assays O
in O
agarose O
gels O
. O
	
one O
patient O
was O
found O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
. O
	
surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
c9 O
, O
which O
was O
functionally O
absent O
. O
	
the O
patient O
was O
shown O
to O
be O
heterozygous O
for O
dna O
markers O
in O
the O
c6 O
, O
c7 O
and O
c9 O
region O
of O
chromosome O
5 O
and O
therefore O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
c9 B-Disease
deficiency I-Disease
genes O
. O
	
serological O
analysis O
by O
elisa O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
c9 O
molecule O
. O
	
western O
blot O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
detection O
of O
this O
molecule O
. O
	
we O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B-Disease
deficiency I-Disease
of I-Disease
c9 I-Disease
and O
for O
a O
gene O
directing O
hyposynthesis O
of O
a O
defective O
c9 O
. O
	
we O
also O
suggest O
that O
c9 B-Disease
deficiency I-Disease
may O
be O
more O
common O
among O
caucasians O
than O
has O
been O
reported O
. O
	
. O
	
screening O
for O
esr O
mutations O
in O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
patients O
. O
	
in O
the O
present O
study O
, O
leukocyte O
dna O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
and O
tumour B-Disease
dna O
from O
96 O
breast B-Disease
carcinomas I-Disease
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
gene O
( O
esr O
) O
. O
	
three O
patients O
with O
a O
family O
history O
of O
cancer B-Disease
were O
carrying O
a O
gly160cys O
germline O
substitution O
. O
	
this O
alteration O
was O
also O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
controls O
( O
366 O
female O
, O
363 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
polymorphism O
. O
	
however O
, O
in O
the O
229 O
female O
controls O
in O
whom O
family O
history O
of O
cancer B-Disease
was O
known O
, O
one O
of O
two O
who O
had O
a O
sister O
with O
breast B-Disease
cancer I-Disease
was O
carrying O
the O
variant O
allele O
. O
	
hence O
, O
a O
possible O
clinical O
significance O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
be O
further O
investigated O
. O
	
somatic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
tumours B-Disease
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
somatic O
esr O
base O
mutations O
as O
an O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen B-Disease
receptor I-Disease
- I-Disease
positive I-Disease
breast I-Disease
carcinomas I-Disease
. O
	
. O
	
molecular O
bases O
of O
c7 B-Disease
deficiency I-Disease
: O
three O
different O
defects O
. O
	
the O
molecular O
basis O
of O
c7 B-Disease
deficiency I-Disease
has O
been O
investigated O
in O
two O
irish O
families O
and O
a O
number O
of O
israeli O
families O
of O
moroccan O
sephardic O
jewish O
origin O
. O
	
exon O
pcr O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
the O
3 O
splice O
acceptor O
site O
of O
intron O
1 O
in O
one O
irish O
family O
. O
	
in O
the O
other O
irish O
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
and O
they O
were O
shown O
to O
be O
deleted O
. O
	
marker O
haplotype O
studies O
of O
the O
c6 O
and O
c7 O
gene O
region O
and O
southern O
blots O
show O
that O
the O
irish O
family O
with O
the O
splice O
defect O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
. O
	
the O
israeli O
c7 B-Disease
- I-Disease
deficient I-Disease
cases O
all O
share O
a O
c7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
sense O
mutation O
in O
exon O
9 O
. O
	
however O
, O
one O
individual O
is O
heterozygous O
for O
markers O
at O
adjacent O
c6 O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
	
. O
	
molecular O
heterogeneity O
of O
classical B-Disease
and I-Disease
duarte I-Disease
galactosemia I-Disease
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O
. O
	
classical B-Disease
galactosemia I-Disease
is O
caused O
by O
one O
common O
missense O
mutation O
( O
q188r O
) O
and O
by O
several O
rare O
mutations O
in O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
galt O
) O
gene O
. O
	
the O
most O
common O
variant O
of O
galt O
, O
the O
duarte O
variant O
, O
occurs O
as O
two O
types O
, O
duarte O
- O
1 O
( O
d O
- O
1 O
) O
and O
duarte O
- O
2 O
( O
d O
- O
2 O
) O
, O
both O
of O
which O
carry O
the O
sequence O
change O
n314d O
. O
	
d O
- O
1 O
increases O
, O
whereas O
d O
- O
2 O
decreases O
galt O
activity O
. O
	
to O
study O
the O
molecular O
genetics O
of O
classical B-Disease
and I-Disease
duarte I-Disease
galactosemia I-Disease
, O
we O
analyzed O
the O
galt O
mutations O
in O
30 O
families O
with O
classical B-Disease
galactosemia I-Disease
, O
in O
10 O
families O
with O
the O
d O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
the O
d O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O
( O
dgge O
) O
. O
	
dgge O
detected O
59 O
of O
the O
60 O
classical O
galactosemia B-Disease
alleles O
. O
	
q188r O
accounted O
for O
60 O
% O
, O
k285n O
accounted O
for O
28 O
% O
of O
these O
alleles O
. O
	
eight O
novel O
candidate O
galactosemia B-Disease
mutations O
were O
found O
. O
	
on O
all O
d O
- O
2 O
alleles O
n314d O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
the O
d O
- O
1 O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
. O
	
we O
conclude O
that O
the O
mutations O
causing O
galactosemia B-Disease
are O
highly O
heterogeneous O
and O
that O
k285n O
is O
a O
second O
common O
galactosemia B-Disease
mutation O
in O
our O
population O
. O
	
. O
	
isolation O
of O
full O
- O
length O
atm O
cdna O
and O
correction O
of O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
cellular O
phenotype O
. O
	
a O
gene O
mutated O
in O
the O
human O
genetic B-Disease
disorder I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
atm O
, O
was O
recently O
identified O
by O
positional O
cloning O
. O
	
atm O
is O
a O
member O
of O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
transduction O
. O
	
we O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cdna O
for O
atm O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
a B-Disease
- I-Disease
t I-Disease
cells O
by O
transfection O
with O
this O
cdna O
. O
	
overexpression O
of O
atm O
cdna O
in O
a B-Disease
- I-Disease
t I-Disease
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
dna O
synthesis O
, O
and O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O
- O
activated O
protein O
kinase O
. O
	
this O
correction O
of O
the O
defects O
in O
a B-Disease
- I-Disease
t I-Disease
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
atm O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
	
. O
	
fusion O
genes O
resulting O
from O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
mechanisms O
in O
alveolar B-Disease
rhabdomyosarcoma I-Disease
. O
	
chromosomal O
translocations O
identified O
in O
hematopoietic B-Disease
and I-Disease
solid I-Disease
tumors I-Disease
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
proteins O
with O
tumorigenic O
potential O
. O
	
in O
the O
pediatric O
solid B-Disease
tumor I-Disease
alveolar B-Disease
rhabdomyosarcoma I-Disease
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
generates O
pax3 O
- O
fkhr O
or O
pax7 O
- O
fkhr O
fusion O
proteins O
, O
respectively O
. O
	
in O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
translocations O
are O
associated O
with O
fusion O
product O
overexpression O
. O
	
furthermore O
, O
pax3 O
- O
fkhr O
and O
pax7 O
- O
fkhr O
overexpression O
occurs O
by O
distinct O
mechanisms O
. O
	
transcription O
of O
pax3 O
- O
fkhr O
is O
increased O
relative O
to O
wild O
- O
type O
pax3 O
by O
a O
copy O
number O
- O
independent O
process O
. O
	
in O
contrast O
, O
pax7 O
- O
fkhr O
overexpression O
results O
from O
fusion O
gene O
amplification O
. O
	
thus O
, O
gene O
- O
specific O
mechanisms O
were O
selected O
to O
overexpress O
pax3 O
- O
fkhr O
and O
pax7 O
- O
fkhr O
in O
alveolar B-Disease
rhabdomyosarcoma I-Disease
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
loci O
. O
	
we O
postulate O
that O
these O
overexpression O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
these O
fusions O
. O
	
. O
	
atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B-Disease
radiation I-Disease
toxicity I-Disease
. O
	
mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B-Disease
- I-Disease
associated I-Disease
diseases I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
and O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
, O
respectively O
. O
	
the O
two O
genes O
are O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
dna O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
. O
	
atm O
- O
nan O
mice O
, O
as O
well O
as O
those O
nan O
for O
p53 O
, O
develop O
mainly O
t B-Disease
- I-Disease
cell I-Disease
lymphomas I-Disease
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
. O
	
to O
study O
the O
interactions O
of O
these O
two O
genes O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
for O
nan O
alleles O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
. O
	
mice O
doubly O
nan O
for O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration O
of O
tumour B-Disease
formation O
relative O
to O
singly O
nan O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
. O
	
with O
respect O
to O
their O
roles O
in O
apoptosis O
, O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
irradiation O
- O
induced O
apoptosis O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
. O
	
this O
implies O
that O
the O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
completely O
congruent O
. O
	
finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B-Disease
radiation I-Disease
toxicity I-Disease
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
dna O
damage O
response O
and O
having O
implications O
for O
the O
prognosis O
and O
treatment O
of O
human O
tumours B-Disease
. O
	
. O
	
trinucleotide O
repeat O
expansion O
at O
the O
myotonic B-Disease
dystrophy I-Disease
locus O
reduces O
expression O
of O
dmahp O
. O
	
myotonic B-Disease
dystrophy I-Disease
, O
or O
dystrophia B-Disease
myotonica I-Disease
( O
dm B-Disease
) O
, O
is O
an O
autosomal B-Disease
dominant I-Disease
multisystem I-Disease
disorder I-Disease
caused O
by O
the O
expansion O
of O
a O
ctg O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
dmpk O
protein O
kinase O
gene O
on O
chromosome O
19q13 O
. O
	
3 O
( O
refs O
1 O
- O
3 O
) O
. O
	
although O
the O
dm B-Disease
mutation O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B-Disease
disease I-Disease
remain O
elusive O
. O
	
previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
dnase O
l O
- O
hypersensitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
allele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
ctg O
- O
repeat O
arrays O
may O
be O
associated O
with O
a O
local O
chromatin O
environment O
that O
represses O
gene O
expression O
. O
	
here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
transcription O
of O
the O
adjacent O
dmahp O
homeobox O
gene O
. O
	
analysis O
of O
dmahp O
expression O
in O
the O
cells O
of O
dm B-Disease
patients O
with O
loss O
of O
the O
hypersensitive O
site O
revealed O
a O
two O
- O
to O
fourfold O
reduction O
in O
steady O
- O
state O
dmahp O
transcript O
levels O
relative O
to O
wild O
- O
type O
controls O
. O
	
allele O
- O
specific O
analysis O
of O
dmahp O
expression O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
. O
	
together O
, O
these O
results O
demonstrate O
that O
ctg O
- O
repeat O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
dmahp O
in O
dm B-Disease
pathogenesis O
. O
	
constitutively O
methylated O
cpg O
dinucleotides O
as O
mutation O
hot O
spots O
in O
the O
retinoblastoma B-Disease
gene O
( O
rb1 O
) O
. O
	
a O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
the O
retinoblastoma B-Disease
gene O
( O
rb1 O
) O
. O
	
mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
homogeneously O
distributed O
. O
	
in O
particular O
, O
a O
significant O
proportion O
of O
disease O
- O
causing O
mutations O
results O
in O
the O
premature O
termination O
of O
protein O
synthesis O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
c O
- O
- O
> O
t O
transitions O
at O
cpg O
dinucleotides O
( O
cpgs O
) O
. O
	
such O
recurrent O
cpg O
mutations O
, O
including O
those O
found O
in O
rb1 O
, O
are O
likely O
the O
result O
of O
the O
deamination O
of O
5 O
- O
methylcytosine O
within O
these O
cpgs O
. O
	
in O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
cytosine O
methylation O
in O
representative O
exons O
of O
rb1 O
. O
	
we O
analyzed O
dna O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
cga O
codons O
in O
rb1 O
, O
where O
recurrent O
premature O
termination O
mutations O
have O
been O
reported O
. O
	
we O
found O
that O
dna O
methylation O
within O
rb1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
be O
restricted O
to O
cpgs O
, O
including O
six O
cga O
codons O
. O
	
other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
to O
be O
mutated O
. O
	
therefore O
, O
disease O
- O
causing O
mutations O
at O
cpgs O
in O
rb1 O
appear O
to O
be O
determined O
by O
several O
factors O
, O
including O
the O
constitutive O
presence O
of O
dna O
methylation O
at O
cytosines O
within O
cpgs O
, O
the O
specific O
codon O
within O
which O
the O
methylated O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
of O
the O
gene O
within O
which O
that O
codon O
resides O
. O
	
. O
	
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
tumor I-Disease
suppressor O
gene O
product O
interacts O
with O
sp1 O
to O
repress O
vascular O
endothelial O
growth O
factor O
promoter O
activity O
. O
	
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
tumor I-Disease
suppressor O
gene O
( O
vhl O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear B-Disease
- I-Disease
cell I-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
( O
rcc B-Disease
) O
, O
as O
vhl O
mutations O
have O
been O
found O
in O
both O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
- I-Disease
associated I-Disease
and I-Disease
sporadic I-Disease
rccs I-Disease
. O
	
recent O
studies O
suggest O
that O
vascular O
endothelial O
growth O
factor O
( O
vegf O
) O
mrna O
is O
upregulated O
in O
rcc B-Disease
- I-Disease
and I-Disease
von I-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
- I-Disease
associated I-Disease
tumors I-Disease
. O
	
we O
have O
therefore O
assessed O
the O
effect O
of O
the O
vhl O
gene O
product O
on O
vegf O
expression O
. O
	
vegf O
promoter O
- O
luciferase O
constructs O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
type O
vhl O
( O
wt O
- O
vhl O
) O
vector O
in O
several O
cell O
lines O
, O
including O
293 O
embryonic O
kidney O
and O
rcc B-Disease
cell O
lines O
. O
	
wt O
- O
vhl O
protein O
inhibited O
vegf O
promoter O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
to O
10 O
- O
fold O
. O
	
deletion O
analysis O
defined O
a O
144 O
- O
bp O
region O
of O
the O
vegf O
promoter O
necessary O
for O
vhl O
repression O
. O
	
this O
vhl O
- O
responsive O
element O
is O
gc O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
sp1 O
in O
crude O
nuclear O
extracts O
. O
	
in O
drosophila O
cells O
, O
cotransfected O
vhl O
represses O
sp1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
vegf O
promoter O
. O
	
we O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
vhl O
and O
sp1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
glutathione O
- O
s O
- O
transferase O
- O
vhl O
fusion O
protein O
and O
purified O
sp1 O
, O
that O
vhl O
and O
sp1 O
directly O
interact O
. O
	
furthermore O
, O
endogenous O
vegf O
mrna O
levels O
were O
suppressed O
in O
permanent O
rcc B-Disease
cell O
lines O
expressing O
wt O
- O
vhl O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
vhl O
regulation O
of O
vegf O
occurs O
at O
least O
partly O
at O
the O
transcriptional O
level O
. O
	
these O
observations O
support O
a O
new O
mechanism O
for O
vhl O
- O
mediated O
transcriptional O
repression O
via O
a O
direct O
inhibitory O
action O
on O
sp1 O
and O
suggest O
that O
loss O
of O
sp1 O
inhibition O
may O
be O
important O
in O
the O
pathogenesis O
of O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
and O
rcc B-Disease
. O
	
. O
	
adult B-Disease
onset I-Disease
globoid I-Disease
cell I-Disease
leukodystrophy I-Disease
( O
krabbe B-Disease
disease I-Disease
) O
: O
analysis O
of O
galactosylceramidase O
cdna O
from O
four O
japanese O
patients O
. O
	
we O
examined O
galactosylceramidase O
( O
galc O
) O
cdna O
in O
four O
japanese O
patients O
with O
adult B-Disease
onset I-Disease
globoid I-Disease
cell I-Disease
leukodystrophy I-Disease
( O
krabbe B-Disease
disease I-Disease
; O
ao B-Disease
- I-Disease
gld I-Disease
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
pcr O
- O
sscp O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
pcr O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B-Disease
paraplegia I-Disease
from O
the O
middle O
of O
the O
second O
decade O
, O
and O
all O
patients O
had O
diminished B-Disease
galc I-Disease
activity I-Disease
in O
their O
leukocytes O
. O
	
we O
identified O
three O
missense O
mutations O
( O
i66m O
, O
g270d O
, O
l618s O
) O
and O
one O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
. O
	
two O
of O
the O
patients O
had O
only O
the O
i66m O
mutant O
mrna O
, O
and O
one O
only O
the O
g27od O
mutant O
mrna O
. O
	
the O
fourth O
patient O
carried O
a O
compound O
heterozygous O
mutation O
of O
535 O
- O
573del O
and O
l618s O
. O
	
to O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
galc O
cdnas O
and O
expressed O
them O
in O
cos O
- O
1 O
cells O
. O
	
three O
mutations O
, O
viz O
. O
	
, O
g270d O
, O
l618s O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
, O
produced O
diminished B-Disease
galc I-Disease
activity I-Disease
as O
expected O
. O
	
the O
i66m O
mutation O
in O
the O
wild O
- O
type O
galc O
cdna O
( O
i289 O
) O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
v289 O
polymorphism O
were O
introduced O
into O
the O
same O
allele O
, O
it O
had O
decreased O
activity O
. O
	
thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
galc O
enzyme O
, O
resulting O
in O
low O
enzymatic O
activity O
. O
	
ao B-Disease
- I-Disease
gld I-Disease
mutations O
, O
including O
those O
found O
here O
, O
are O
located O
in O
the O
n O
- O
terminus O
( O
i66m O
, O
g270d O
, O
535 O
- O
573del O
) O
or O
c O
- O
terminus O
( O
l618s O
) O
of O
the O
galc O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form O
( O
if B-Disease
- I-Disease
gld I-Disease
) O
are O
in O
the O
central O
domain O
. O
	
this O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
features O
of O
gld B-Disease
. O

the O
results O
showed O
that O
enriched O
ginger B-Plant
extract O
rhizomes O
exhibited O
the O
highest O
anti O
cancer B-Disease
activity O
on O
mcf O
7 O
cancer B-Disease
cells O
with O
ic50 O
values O
of O
34 O
8 O
and O
25 O
7 O
g O
ml O
for O
fulbaria O
and O
syedpuri O
respectively O

the O
use O
of O
ginger B-Plant
grown O
under O
elevated O
co2 O
concentration O
may O
have O
potential O
in O
the O
treatment O
and O
prevention O
of O
cancer B-Disease

projected O
effects O
of O
tobacco B-Plant
smoking O
on O
worldwide O
tuberculosis B-Disease
control O
mathematical O
modelling O
analysis O

the O
model O
estimated O
that O
aggressive O
tobacco B-Plant
control O
achieving O
a O
1 O
decrease O
in O
smoking O
prevalence O
per O
year O
down O
to O
eradication O
would O
avert O
27 O
million O
smoking O
attributable O
deaths O
from O
tuberculosis B-Disease
by O
2050 O

however O
if O
the O
prevalence O
of O
smoking O
increased O
to O
50 O
of O
adults O
as O
observed O
in O
countries O
with O
high O
tobacco B-Plant
use O
the O
model O
estimated O
that O
34 O
million O
additional O
deaths O
from O
tuberculosis B-Disease
would O
occur O
by O
2050 O

conclusions O
tobacco B-Plant
smoking O
could O
substantially O
increase O
tuberculosis B-Disease
cases O
and O
deaths O
worldwide O
in O
coming O
years O
undermining O
progress O
towards O
tuberculosis B-Disease
mortality O
targeta O
aggressive O
tobacco B-Plant
control O
could O
avert O
millions O
of O
deaths O
from O
tuberculosis B-Disease

elastase O
is O
the O
only O
currently O
identified O
target O
protein O
for O
indole O
3 O
carbinol O
i3c O
a O
naturally O
occurring O
hydrolysis O
product O
of O
glucobrassicin O
in O
cruciferous B-Plant
vegetables I-Plant
such O
as O
broccoli B-Plant
cabbage B-Plant
and O
brussels B-Plant
sprouts I-Plant
that O
induces O
a O
cell O
cycle O
arrest O
and O
apoptosis O
of O
human O
breast B-Disease
cancer I-Disease

toward O
the O
identification O
of O
communities O
with O
increased O
tobacco B-Plant
associated O
cancer B-Disease
burden O
application O
of O
spatial O
modeling O
techniques O

identifying O
areas O
with O
higher O
than O
average O
cancer B-Disease
risk O
and O
smoking O
rates O
then O
targeting O
those O
areas O
for O
intervention O
is O
one O
approach O
to O
more O
rapidly O
lower O
the O
overall O
tobacco B-Plant
disease O
burden O
in O
a O
given O
states O

our O
research O
team O
used O
spatial O
modeling O
techniques O
to O
identify O
areas O
in O
florida O
with O
higher O
than O
expected O
tobacco B-Plant
associated O
cancer B-Disease
incidence O
clusters O

materials O
and O
methods O
geocoded O
tobacco B-Plant
associated O
incident O
cancer B-Disease
data O
from O
1998 O
to O
2002 O
from O
the O
florida O
cancer O
data O
system O
were O
used O

tobacco B-Plant
associated O
cancers B-Disease
included O
lung B-Disease
esophageal B-Disease
and O
h B-Disease
n I-Disease
cancers I-Disease

satscan O
was O
used O
to O
identify O
geographic O
areas O
that O
had O
statistically O
significant O
p O
0 O
10 O
excess O
age O
adjusted O
rates O
of O
tobacco B-Plant
associated O
cancers B-Disease

however O
spatial O
analyses O
may O
be O
most O
useful O
when O
examining O
incident O
clusters O
where O
several O
tobacco B-Plant
associated O
cancer B-Disease
clusters O
overlap O

focusing O
on O
overlapping O
cancer B-Disease
clusters O
may O
help O
investigators O
identify O
priority O
areas O
for O
further O
screening O
detailed O
assessments O
of O
tobacco B-Plant
use O
and O
or O
prevention O
and O
cessation O
interventions O
to O
decrease O
risk O

epidemiological O
evidence O
shows O
that O
regular O
consumption O
of O
brassicaceae B-Plant
is O
associated O
with O
a O
reduced O
risk O
of O
cancer B-Disease
and O
heart B-Disease
disease I-Disease

coriander B-Plant
has O
been O
recommended O
for O
the O
relief O
of O
pain B-Disease
anxiety B-Disease
flatulence B-Disease
and O
loss B-Disease
of I-Disease
appetite I-Disease

in O
traditional O
medicine O
it O
is O
believed O
that O
coriander B-Plant
can O
induce O
some O
degree O
of O
amnesia B-Disease
in O
a O
child O
when O
his O
her O
mother O
uses O
coriander B-Plant
during O
the O
pregancy O

no O
modification O
in O
the O
pain B-Disease
threshold O
was O
elicited O
by O
electric O
stimuli O
both O
in O
coriander B-Plant
and O
control O
groups O

perceived O
health O
risks O
attitude O
and O
readiness O
to O
quit O
tobacco B-Plant
among O
euthymic B-Disease
bipolar I-Disease
disorder I-Disease
patients O
in O
regular O
contact O
with O
mental O
health O
services O
an O
exploratory O
study O
from O
india O

background O
patients O
with O
bipolar O
disorder O
bd B-Disease
are O
at O
higher O
risk O
of O
tobacco B-Plant
related O
harm O
compared O
with O
general O
population O

aim O
the O
study O
aims O
to O
explore O
the O
perceived O
health O
risks O
attitude O
and O
readiness O
to O
quit O
tobacco B-Plant
among O
euthymic O
bd B-Disease
patients O

the O
non O
readiness O
to O
change O
tobacco B-Plant
use O
was O
predicted O
by O
difficulty O
in O
quitting O
due O
to O
mood B-Disease
disorder I-Disease
odds O
ratio O
or O
0 O
229 O
and O
a O
higher O
perceived O
ability O
to O
quit O
or O
328 O

conclusion O
the O
knowledge O
and O
risk O
perception O
for O
tobacco B-Plant
remains O
inadequate O
even O
among O
the O
stable O
bd B-Disease
type I-Disease
i I-Disease
patients O
in O
regular O
contact O
with O
mental O
health O
services O

the O
aim O
of O
this O
review O
is O
to O
summarize O
present O
knowledge O
of O
genetic O
variation O
in O
cytochrome O
p450 O
1b1 O
cyp1b1 O
and O
2c9 O
cyp2c9 O
genes O
and O
risk O
of O
tobacco B-Plant
related O
cancer B-Disease
female O
cancer B-Disease
chronic B-Disease
obstructive I-Disease
pulmonary I-Disease
disease I-Disease
and O
ischemic B-Disease
vascular I-Disease
disease I-Disease

recently O
large O
studies O
on O
the O
association O
between O
genetic O
variation O
in O
cyp1b1 O
and O
cyp2c9 O
and O
risk O
of O
disease O
with O
considerable O
statistical O
power O
rebutted O
the O
hypotheses O
that O
these O
genetic O
variants O
affect O
risk O
of O
tobacco B-Plant
related O
cancer B-Disease
female O
cancer B-Disease
chronic B-Disease
obstructive I-Disease
pulmonary I-Disease
disease I-Disease
and O
ischemic B-Disease
vascular I-Disease
disease I-Disease

fenugreek B-Plant
a O
naturally O
occurring O
edible O
spice O
kills O
mcf O
7 O
human O
breast B-Disease
cancer I-Disease
cells O
via O
an O
apoptotic O
pathway O

trigonella B-Plant
foenum I-Plant
graecum I-Plant
fenugreek B-Plant
is O
traditionally O
applied O
to O
treat O
disorders O
such O
as O
diabetes B-Disease
high B-Disease
cholesterol I-Disease
wounds B-Disease
inflammation B-Disease
and O
gastrointestinal B-Disease
ailments I-Disease

oxyresveratrol O
is O
a O
potent O
antioxidant O
and O
free O
radical O
scavenger O
found O
in O
mulberry B-Plant
wood I-Plant
morus B-Plant
alba I-Plant
l I-Plant
with O
demonstrated O
protective O
effects O
against O
cerebral B-Disease
ischemia I-Disease

background O
olive B-Plant
oil O
consumption O
is O
associated O
with O
a O
decreased O
risk O
of O
several O
chronic B-Disease
diseases I-Disease
in O
particular O
cardiovascular B-Disease
disease I-Disease
cvd B-Disease

objective O
we O
evaluated O
the O
association O
between O
olive B-Plant
oil O
and O
overall O
and O
cause O
specific O
mortality O
in O
the O
spanish O
population O
in O
the O
european O
prospective O
investigation O
into O
cancer B-Disease
and O
nutrition O
epic O
spain O

the O
association O
between O
olive B-Plant
oil O
analyzed O
as O
a O
categorical O
and O
continuous O
variable O
and O
overall O
and O
cause O
specific O
mortality O
cvd B-Disease
cancer B-Disease
and O
other O
causes O
was O
analyzed O
by O
using O
cox O
proportional O
hazards O
regression O
models O
adjusted O
for O
potential O
confounders O

in O
comparison O
with O
nonconsumers O
the O
highest O
quartile O
of O
olive B-Plant
oil O
consumption O
was O
associated O
with O
a O
26 O
95 O
ci O
13 O
36 O
reduction O
in O
risk O
of O
overall O
mortality O
and O
a O
44 O
95 O
ci O
21 O
60 O
reduction O

in O
cvd B-Disease
for O
each O
increase O
in O
olive B-Plant
oil O
of O
10gr O
2000 O
kcal O
d O
there O
was O
a O
7 O
95 O
ci O
3 O
10 O
decreased O
risk O
of O
overall O
mortality O
and O
a O
13 O
95 O
ci O
6 O
20 O
decreased O
risk O
of O
cvd B-Disease
mortality O
no O
significant O
association O
was O
observed O
between O
olive B-Plant
oil O
and O
cancer B-Disease
mortality O

conclusions O
olive B-Plant
oil O
was O
associated O
with O
a O
decreased O
risk O
of O
overall O
mortality O
and O
an O
important O
reduction O
in O
cvd B-Disease
mortality O
in O
this O
large O
mediterranean O
cohort O

areca B-Plant
nut O
chewing O
and O
systemic B-Disease
inflammation I-Disease
evidence O
of O
a O
common O
pathway O
for O
systemic B-Disease
diseases I-Disease

diabetes B-Disease
hypertension B-Disease
cardiovascular B-Disease
diseases I-Disease
oropharyngeal B-Disease
and O
oesophageal B-Disease
cancers I-Disease
have O
been O
associated O
with O
areca B-Plant
nut O
chewing O
and O
the O
mechanism O
by O
which O
areca B-Plant
nut O
chewing O
increases O
the O
risk O
of O
systemic B-Disease
diseases I-Disease
remains O
elusive O

we O
hypothesize O
that O
systemic B-Disease
inflammation I-Disease
may O
be O
elevated O
among O
areca B-Plant
nut O
users O
which O
is O
linked O
with O
many O
systemic B-Disease
disease I-Disease

therefore O
this O
present O
study O
was O
conducted O
to O
examine O
the O
systemic B-Disease
inflammation I-Disease
among O
areca B-Plant
nut O
chewers O
and O
healthy O
control O

increase O
in O
amount O
of O
areca B-Plant
nut O
consumption O
had O
a O
significant O
dose O
response O
relationship O
with O
systemic B-Disease
inflammation I-Disease
p O
for O
trend O

areca B-Plant
nut O
chewing O
has O
a O
significant O
association O
with O
systemic B-Disease
inflammation I-Disease

further O
work O
is O
required O
to O
confirm O
that O
systemic B-Disease
inflammation I-Disease
is O
the O
main O
pathway O
by O
which O
areca B-Plant
nut O
use O
increases O
the O
risk O
of O
systemic B-Disease
diseases I-Disease

rhodiola B-Plant
crenulata I-Plant
root O
ameliorates O
derangements O
of O
glucose O
and O
lipid O
metabolism O
in O
a O
rat O
model O
of O
the O
metabolic B-Disease
syndrome I-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease

ethnopharmacological O
relevance O
rhodiola B-Plant
species O
are O
traditionally O
used O
as O
tonics O
and O
stimulants O
to O
treat O
asthenia B-Disease
suggesting O
their O
possible O
regulatory O
effect O
on O
energy O
metabolism O

materials O
and O
methods O
zucker O
diabetic B-Disease
fatty O
zdf O
rats O
were O
treated O
with O
rhodiola B-Plant
crenulata I-Plant
root O
rcr B-Plant
powder O
100 O
and O
500 O
mg O
kg O
by O
gavage O
once O
daily O
for O
4 O
weeks O

in O
addition O
the O
effects O
of O
rcr B-Plant
on O
sucrose O
induced O
acute O
hyperglycemia B-Disease
in O
mice O
and O
olive B-Plant
oil O
induced O
hypertriglyceridemia B-Disease
in O
rats O
were O
also O
examined O

however O
rcr B-Plant
minimally O
affected O
sucrose O
induced O
acute O
hyperglycemia B-Disease
in O
mice O
and O
olive B-Plant
oil O
induced O
acute O
hypertriglyceridemia B-Disease
in O
rats O

conclusions O
the O
present O
results O
demonstrate O
that O
rcr B-Plant
treatment O
improves O
metabolic O
derangements O
in O
animal O
model O
of O
the O
metabolic B-Disease
syndrome I-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease

persistent O
cigarette O
smoking O
and O
other O
tobacco B-Plant
use O
after O
a O
tobacco B-Plant
related O
cancer B-Disease
diagnosis O

these O
risks O
may O
be O
even O
higher O
among O
tobacco B-Plant
related O
cancer B-Disease
survivors O
trcs O

we O
describe O
tobacco B-Plant
use O
behaviors O
among O
trcs O
other O
cancer B-Disease
survivors O
and O
people O
without O
a O
history O
of O
cancer B-Disease

methods O
we O
used O
2009 O
behavioral O
risk O
factor O
surveillance O
system O
data O
to O
describe O
demographic O
characteristics O
smoking O
history O
current O
smoking O
prevalence O
and O
smokeless O
tobacco B-Plant
use O
among O
trcs O
other O
cancer B-Disease
survivors O
and O
people O
without O
a O
history O
of O
cancer B-Disease
cigarette O
smoking O
and O
smokeless O
tobacco B-Plant
use O
were O
calculated O
after O
adjusting O
for O
age O
sex O
race O
and O
insurance O
status O

tobacco B-Plant
related O
cancers B-Disease
were O
defined O
as O
lung O
bronchial O
pharyngeal O
laryngeal O
esophageal O
stomach O
pancreatic O
kidney O
renal O
urinary O
bladder O
cervical O
and O
acute B-Disease
myeloid I-Disease
leukemia I-Disease

smokeless O
tobacco B-Plant
use O
was O
higher O
among O
respondents O
without O
a O
history O
of O
cancer B-Disease
4 O
compared O
with O
trcs O
3 O
and O
other O
cancer B-Disease
survivors O
3 O

targeted O
smoking O
prevention O
and O
cessation O
interventions O
are O
needed O
for O
cancer B-Disease
survivors O
especially O
those O
diagnosed O
with O
a O
tobacco B-Plant
related O
cancer B-Disease

we O
provide O
the O
first O
population O
based O
report O
on O
demographic O
characteristics O
and O
tobacco B-Plant
use O
behaviors O
among O
sel O
reported O
tobacco B-Plant
related O
cancer B-Disease
survivors O

epidemiological O
studies O
suggest O
that O
cocoa B-Plant
rich O
products O
reduce O
the O
risk O
of O
cardiovascular B-Disease
disease I-Disease

epidemiological O
studies O
suggest O
that O
cocoa B-Plant
rich O
products O
reduce O
the O
risk O
of O
cardiovascular B-Disease
disease I-Disease

adverse O
effects O
including O
gastrointestinal B-Disease
complaints I-Disease
and O
distaste O
of O
the O
trial O
product O
were O
reported O
by O
5 O
of O
patients O
in O
the O
active O
cocoa B-Plant
intervention O
group O
and O
1 O
of O
patients O
in O
the O
control O
groups O

furthermore O
long O
term O
trials O
investigating O
the O
effect O
of O
cocoa B-Plant
on O
clinical O
outcomes O
are O
also O
needed O
to O
assess O
whether O
cocoa B-Plant
has O
an O
effect O
on O
cardiovascular B-Disease
events I-Disease
and O
to O
assess O
potential O
adverse O
effects O
associated O
with O
chronic O
ingestion O
of O
cocoa B-Plant
products O

aloe B-Plant
emodin O
an O
anthraquinone O
in O
vitro O
inhibits O
proliferation O
and O
induces O
apoptosis O
in O
human O
colon B-Disease
carcinoma I-Disease
cells O

the O
present O
study O
aimed O
to O
investigate O
the O
anticancer O
effect O
of O
aloe B-Plant
emodin O
an O
anthraquinone O
compound O
present O
in O
the O
leaves O
of O
aloe B-Disease
vera I-Disease
on O
two O
human O
colon B-Disease
carcinoma I-Disease
cell O
lines O
dld O
and O
widr O

colon B-Disease
carcinoma I-Disease
cells O
were O
treated O
with O
various O
concentrations O
of O
aloe B-Plant
emodin O
for O
different O
durations O

in O
addition O
exposure O
of O
colon B-Disease
carcinoma I-Disease
cells O
to O
aloe B-Plant
emodin O
suppressed O
the O
casein O
kinase O
ii O
activity O
in O
a O
time O
dependent O
manner O
and O
was O
accompanied O
by O
a O
reduced O
phosphorylation O
of O
bid O
a O
downstream O
substrate O
of O
casein O
kinase O
ii O
and O
a O
pro O
apoptotic O
molecule O

these O
findings O
showed O
that O
the O
inhibition O
of O
casein O
kinase O
ii O
activity O
the O
release O
of O
apoptosis O
inducing O
factor O
and O
cytochrome O
c O
and O
the O
caspase O
3 O
activation O
are O
involved O
in O
aloe B-Plant
emodin O
mediated O
apoptosis O
in O
colon B-Disease
carcinoma I-Disease
cells O

in O
this O
study O
we O
use O
a O
genomic O
approach O
to O
study O
the O
signaling O
processes O
associated O
with O
tobacco B-Plant
smoke O
exposure O
and O
lung B-Disease
cancer I-Disease

furthermore O
our O
findings O
suggest O
that O
the O
airway O
gene O
expression O
signatures O
derived O
in O
this O
study O
can O
provide O
novel O
insights O
into O
signaling O
pathways O
altered O
in O
the O
field O
of O
injury O
induced O
by O
tobacco B-Plant
smoke O
and O
thus O
may O
impact O
strategies O
for O
prevention O
of O
tobacco B-Plant
related O
lung B-Disease
cancer I-Disease

effects O
of O
korean O
red O
ginseng B-Plant
extracts O
on O
neural B-Disease
tube I-Disease
defects I-Disease
and O
impairment B-Disease
of I-Disease
social I-Disease
interaction I-Disease
induced O
by O
prenatal O
exposure O
to O
valproic O
acid O

using O
the O
prenatal O
valproic O
acid O
vpa O
injection O
model O
of O
autism B-Disease
spectrum I-Disease
disorder I-Disease
asd B-Disease
in O
rats O
which O
produces O
social O
impairrment O
and O
altered O
seizure B-Disease
susceptibility O
as O
in O
human O
asd B-Disease
patients O
as O
well O
as O
mild O
neural B-Disease
tube I-Disease
defects I-Disease
like O
crooked B-Disease
tail I-Disease
phenotype I-Disease
we O
examined O
whether O
chronic O
administration O
of O
red O
ginseng B-Plant
extract O
may O
rescue O
the O
social O
impairment O
and O
crooked B-Disease
tail I-Disease
phenotype I-Disease
in O
prenatally O
vpa O
exposed O
rat O
offspring O

vpa O
induced O
impairment O
in O
social O
interactions O
tested O
using O
sociability O
and O
social O
preference O
paradigms O
as O
well O
as O
crooked B-Disease
tail I-Disease
phenotypes I-Disease
were O
significantly O
improved O
by O
administration O
of O
korean O
red O
ginseng B-Plant
krg B-Plant
in O
a O
dose O
dependent O
manner O